Dan:

Please bring this to the attention of appropriate NIAID people.

Thanks,
Tony

>
On Apr 19, 2020, at 10:34 PM, Charles McCall wrote:
>
Dear Tony and Dan,

>
>
>
Thank you for considering this idea. Be safe.
> Cash

> Sent from iPad
> Charles (Cash) McCall, MD
> Professor of Internal Medicine, Translational Sciences, Microbiology & Immunology
> Wake Forest University School of Medicine
> Wake Forest Biotech Place, suite 350, room 3W-007
> 575 N. Patterson Avenue
> Winston-Salem, NC 27101
>
Set up

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-0440
E-mail: (301) 496-0440

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: O'Connor, Eileen <EOConnor@rockfound.org>
Sent: Monday, April 20, 2020 7:47 AM
To: Fauci, Anthony (NIH/NIAID) [E] <AFAUCI@niaid.nih.gov>; Anthony.s/fauci@nih.gov;
Subject: A National Testing Action Plan by the Rockefeller Foundation: Embargoed till midnight Monday April 20

Dear Tony:

Thank you for all you are doing. Not sure you remember me, but we talked a lot when I was at CNN. I have not wanted to bother you but wanted to make sure you had the National Testing Action Plan that we have put together with top researchers from all the various roadmaps, etc. I joined The Rockefeller Foundation after working in Afghanistan and Pakistan with State and coerced Christy Feig to join me. We would be happy to get on a call today with Raj and Jonathan Quick and other authors like Mike Pellini and Mark McLellan and Rick Klausner.

Given our history with public health and our ability to convene, we hoped we could help by working out a consensus plan. I have been briefing Caleb McCarry at the White House. We have worked with industry to also figure out the solutions to the supply chain issues and the
other logistical issues. We are going to put $10 million into helping this standup. This plan
doesn't just say what we need but the steps to get it done to open more safely.

Please let me know if you would like a call.

Regards
Eileen

Eileen O'Connor
Senior Vice President
Communications, Policy and Advocacy
The Rockefeller Foundation
Office: 212 852 8436
Mobile: (b) (b)
eoconnor@rockfound.org
www.rockfound.org
(For scheduling purposes, please contact my assistant, (b) (b), at
(b) (b)
Please handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [b][6]
FAX: (301) 496-4409
E-mail: [b][6]

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

[b][6]
Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage device. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender’s own and not expressly made on behalf of the NIAID by one of its representatives.

You have an interview today with Jack Curry of the YES Network (Yankees). Just last night, The NY Post ran a story that includes Jack among the many sports broadcasting stars that have come out of Fordham (b) (6); Jack and I have talked about this. Thought you might like to see it. Parts of your interview are also going to run on Michael Kay’s show, and Kay also features prominently in this piece.

How Fordham has produced a generation of sports media stars

April 19, 2020 | 4:04pm | Updated April 19, 2020 | 9:16pm
Long before he was an electee to the Basketball Hall of Fame, Mike Breen was an intimidated 18-year-old freshman attending a workshop at Fordham’s renowned college radio station, WFUV, in the fall of 1979.

Breen felt sheepish next to the juniors and seniors leading the seminar and contemplated delaying the start of his broadcasting training. Soon, a couple of upperclassmen, including future NBA writer Dave D’Alesandro, made him feel more comfortable.

But he still didn’t have any friends until one day on campus he saw a confident sophomore trying to sweet talk a young woman. “I know you like me,” he said. “I can see it in your eyes.”

The woman responded by saying she would not date him if he were the last man on earth. She essentially was saying, “See ya” … to Michael Kay.

That is how Breen first became friends with Kay.

“For him to have the confidence to do this in front of everybody with this beautiful student, I thought, ‘Man, this guy has a great sense of humor,’” Breen said.

Four decades later, Breen and Kay are still good friends.
Fordham, the private Jesuit university in The Bronx that launched the legendary Vin Scully, for decades has been a powerhouse sportscasting pipeline, especially in New York. And the school ties that first united Breen and Kay are webbed throughout the industry.

Fordham is the alma mater for the voice of the NBA Finals/Knicks (Breen, Class of 1983), the Yankees’ lead TV play-by-player/ESPN New York afternoon radio host (Kay, ’82), the voice of the Giants (Bob Papa, ’86), the radio voice of the Nets (Chris Carrino, ’92) MSG’s John Giannone (’86), YES’ Jack Curry (’86), WFAN’s Paul Dottino (’86) and YES/ESPN’s Ryan Ruocco (’08). And that’s just New York-based sportscasters.

For good measure, the school produced CBS’ Spero Dedes (’01), ESPN’s Tony Reali (’00) and the Washington Nationals’ Charlie Slowes (’83). There are many more, and not just in front of the camera. If you need a field producer, Jim Johnson (’86) works for ESPN. A radio engineer? WFAN’s Chris Majkowski (’89) will set things up. Media relations? Louis Barricelli (’09) is leading things at MLB Network.

Like everyone else, they are all dealing with the halt of sports due to the coronavirus pandemic. It is a jarring timeout for people so used to being on the run.
Take Carrino, who has done so much to raise money and awareness for facio scapulo humeral dystrophy (FSHD), a form of muscular dystrophy that afflicts him. A fundraising event was supposed to take place in March at a Nets game at Barclays Center. His 10th annual fundraising dinner, corresponding with his 50th birthday, was slated for August, and now is in question.

“I don’t know if it is going to be safe to have people together still,” Carrino said. “Are the restrictions going to be there in terms of how many people can gather in one place? The other aspect of it for me is: How comfortable am I asking people for money when I know the economy and certain businesses are affected so badly?”

Ruocco was supposed to get married in Italy in June. He and his fiancée, Andrea Ferrizco, are now going to punt the wedding until June 2021.

“It sucks,” Ruocco said. “Andrea and I were so excited and so were our guests. We have been feeling all the joy leading up to this. There are people dealing with much more dire circumstances than rescheduling a wedding. That is kind of the perspective we have tried to take.”

While most of the successful sports media alumni are worried about the current direction of Fordham and WFUV because of a de-emphasis on sports during the pandemic, to a man they say how Fordham molded them and led them to where they are today.

They were helped by famous names such as the legendary Marty Glickman, a mentor, and Stan Fischler, who taught classes. Then there were the less famous, equally instrumental figures in the program, such as Bob Ahrens, who ran WFUV as its executive producer during many of these notable students’ formative years.
The experiences that they shared forged many of them, such as Breen and Kay, into close friends.

Giannone went to Fordham after being recruited to be a punter on the football team. During training camp his freshman year, he quickly figured out the third-string punter would never see the field. He went to Kay, then the WFUV sports director as a senior, to try to help on the station. Kay said Giannone could do stats for him during the football season.

Kay went on to work at The Post, and later helped Giannone land an entry-level position at the paper. When Giannone transferred into television at CNN/Sports Illustrated, it was through a Kay connection. And Giannone landed at MSG Network after Kay left to become the TV voice of the Yankees when YES Network began.

When it was Giannone’s turn as WFUV sports director, he made Papa and Curry a play-by-play player and an analyst when they were sophomores.

WFUV also got its staff access to locker rooms at places like Yankee Stadium and Madison Square Garden to learn the craft next to professionals at the highest level. That remains largely true today.

“WFUV allowed you to believe you were a professional broadcaster before you really were,” Curry said. “We were in the heart of New York City, and, even if we weren’t Marv Albert, we felt as if what Marv Albert was doing for the Knicks, we were doing for Fordham.”

There is a lineage that unites. Carrino learned how to describe the geography of a basketball court from Glickman. Later, Carrino returned to Fordham and taught Ruocco the same lessons. These days, at some Nets games, Ruocco is on TV, sitting next to Carrino, calling the game on the radio.
Papa also was mentored by Glickman. Papa and Carrino each were told by their fathers that if they majored in communications, they would have to pay for school themselves. Both ended up in the Business School, but had their eyes on WFUV the whole time.

Carrino ended up working as a producer for Papa, beginning when Papa hosted a tailgate show on WFAN. Carrino eventually followed Papa as the radio voice of the Nets.

The Fordham sports alums want everyone to be safe during this time — and they can’t wait to get back to what they love to do.

“I’m desperate to get back to work,” Breen said. “I’m hoping there is NBA basketball. This is the best time of the year.”
Email below is from Larry Corey.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: 
Email: 

Here is the working draft of the article for the NEJM. It, in my opinion, reads really well. I have embellished it today with a figure that conceptually outlines what we are talking about; the old axiom that a picture is worth a thousand words.

The editorial guidelines of the NEJM has 2 potential categories. One is Perspectives which is 1200 words and 5 references. We are at 1750 words and I think losing 500 words takes away a lot from the message. The other category is a special report which is over 2500 words and allows lots of references (40). I think this is best and was one reason I thought about adding the conceptual figure which does outline in a single picture what we are talking about.

Tony, If you feel its best to have Francis on this paper we both support it. Your call. I do however lean on including Francis. I would say politically to achieve our goal and bring these companies into the tent while you are away at the White House having him buy into this plan through the ACTIV program seems important to us. I think we get to our goal if he is out there publicly embracing this; using the NIAID networks labs DSMB and the correlates programs. This type of granularity really puts him deep into understanding what we are doing. If this means you are first and he is last author we are ok with that. For me I need to have him use me for interfacing with the company in defining these collaborations. If you were present all the time this would be unnecessary, but as he will be the link with BARDA linking him to John and I increases the likelihood of success.
Ok enough .. as they say on the news Goodnight..

Larry
Thanks, Tom!

Hi Tony,
It was great to see you and present our work to you this last Friday. I really enjoyed our discussion and feedback.
As I said on zoom, we all really appreciate your leadership in the COVID-19 crisis. Thank you for providing the guiding way through this.

In the meantime, your photos are getting passed around and Hunter Handsfield wanted you to have this one (from the HIV archives—1983 in Seattle).

All the best,
Tom

p.s. Stay healthy!

Hi, Tom. Going through old boxes I came across this, from 5th ISSTDR, Seattle 1983. Give Tony my greetings if you forward to him.

Cheers— Hunter
H. Hunter Handsfield, MD
Professor Emeritus of Medicine
Center for AIDS and STD
University of Washington

Phone +1 206 935-5225
Mobile (b) (8)
Email from Tom Quinn to you.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b)(6)
Email: (b)(6)

From: Thomas Quinn (b)(6)
Sent: Sunday, April 19, 2020 6:28 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b)(6)>
Cc: Hunter Handsfield <hhh@uw.edu>
Subject: FW: Fauci photo

Hi Tony,
It was great to see you and present our work to you this last Friday. I really enjoyed our discussion and feedback.
As I said on zoom, we all really appreciate your leadership in the COVID-19 crisis. Thank you for providing the guiding way through this.

(b)(4)

In the meantime, your photos are getting passed around and Hunter Handsfield wanted you to have this one (from the HIV archives—1983 in Seattle).

All the best,
Tom

p.s. (b)(6). Stay healthy!
Hi, Tom. Going through old boxes I came across this, from 5th ISSTDR, Seattle 1983. Give Tony my greetings if you forward to him.

Cheers — Hunter

H. Hunter Handsfield, MD
Professor Emeritus of Medicine
Center for AIDS and STD
University of Washington
Email from David Liu to FC with a cc to you.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

From: David R. Liu
Sent: Sunday, April 19, 2020 9:08 PM
To: Collins, Francis (NIH/OD) [E] (b) (6)
Cc: Michael Rosbash (b) (6); Ramnik Xavier (b) (6); EDWARD SCOLNICK (b) (6); Stuart Schreiber (b) (6); Michael Z Lin (b) (6); Ben Cravatt (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Austin, Christopher (NIH/NCATS) [E] (b) (6); Wholley, David (FNIH) [T] (b) (6); Freire, Maria (FNIH) [T] (b) (6); Tabak, Lawrence (NIH/OD) [E] (b) (6); Thomas Cahill (b) (6)
Subject: Re: A proposal to stop COVID-19 and reopen our schools and businesses

Thank you, Francis, for your speedy reply. Please let us know if we can help ACTIV, Fauci, or any other leaders who might want to engage.

Best,
David

David R. Liu
Richard Merkin Professor and Director of the Merkin Institute
of Transformative Technologies in Healthcare
Broad Institute Core Institute Member and Vice-Chair of the Faculty
Director of the Chemical Biology and Therapeutic Sciences Program
Howard Hughes Medical Institute Investigator
Harvard University Professor of Chemistry and Chemical Biology
75 Ames Street
Cambridge, MA 02142
On Apr 19, 2020, at 8:48 PM, Collins, Francis (NIH/OD) [E] (b) (6)> wrote:

Dear David et al.,

Thanks for forwarding this very thoughtful document, which presents a series of important recommendations – most of which I agree with. I don’t know if you saw Friday’s announcement (attached) of the new public private partnership called ACTIV (for Accelerating COVID-19 Therapeutic Interventions and Vaccines), but it has taken on most of the points you raise in sections 1–3 of your letter. I share your hopes that remdesivir will show benefit, and the current large NIH-sponsored RCT has completed enrollment and should reveal results in about a month. But of course we want to test multiple other interventions – both small molecules and antibody-based therapies, so we need our trial system to be optimized like never before. I will share your letter with the leaders of ACTIV, who are working with unprecedented speed to prioritize the next set of therapeutic candidates as well as pushing vaccine development programs to adopt exceptionally creative trial designs to test safety and efficacy (with full engagement by FDA).

Best regards, Francis

From: David Liu (b) (6)
Sent: Sunday, April 19, 2020 5:20 PM
To: OD Labc (NIH/OD) (b) (6); Collins, Francis (NIH/OD) [E] (b) (6)
Cc: Michael Rosbash (b) (6); Ramnik Xavier (b) (6); EDWARD SCOLNICK (b) (6); Stuart Schreiber (b) (6); Michael Z Lin (b) (6); Ben Cravatt (b) (6)
Subject: A proposal to stop COVID-19 and reopen our schools and businesses

Dear Francis,

I hope you are well.

I write on behalf of a group of citizen-scientists, most or all of whom you know. Motivated solely by our desire to help defeat the serious threat our nation and the world now faces, we wrote a set of four actionable, non-partisan proposals (attached) to produce safe and effective COVID-19 therapeutics and vaccines in the shortest possible timeframe, and to reopen our society in a manner that reduces the risk of future COVID-19 outbreaks.

We hope you find these ideas interesting, and might be willing to share this set of proposals with Dr. Tony Fauci, along with our willingness to discuss any part of the
proposals with him if we can be helpful. We understand from our efforts to contact Dr. Fauci through email routes that his standard inbox may be too overwhelmed for our proposal to reach him.

The four proposals attached describe: (1) How to rapidly repurpose an antiviral drug to treat COVID-19 patients; (2) How to expedite the development of human antibody drugs to treat patients and to provide short-term protection for healthy individuals; (3) How to develop COVID-19 vaccines on an expedited time scale; and (4) How to reopen our businesses and schools in a manner that reduces the risk of future outbreaks and deaths.

Thank you for any help or thoughts you might be able to provide.

Sincerely yours,
Ben Cravatt (Scripps), Lynn Goldman (GWU), Akiko Iwasaki (Yale), Scott Kemp (MIT), Michael Lin (Stanford), David Liu (Harvard/Broad), Michael Rosbash (Brandeis), Stuart Schreiber (Harvard/Broad), Ed Scollnick (Broad), Jonathan Simons (PCF), and Ramnik Xavier (MGH/Broad)

David R. Liu
Richard Merkin Professor and Director of the Merkin Institute
of Transformative Technologies in Healthcare
Director of the Chemical Biology and Therapeutic Sciences Program
Core Institute Member and Vice-Chair of the Faculty, Broad Institute
Investigator, Howard Hughes Medical Institute
Thomas Dudley Cabot Professor of the Natural Sciences
and Professor of Chemistry & Chemical Biology, Harvard University
75 Ames Street
Cambridge, MA 02142

<NIH_ACTIV_Release_041720.docx>
From: Fauci, Anthony (NIH/NIAID) [E]  
Sent: Mon, 20 Apr 2020 01:25:42 +0000  
To: bgertz@washingtontimes.com  
Cc: Miller, Katie R. EOP/OVP; Short, Marc T. EOP/OVP  
Subject: Scientific paper on origin of coronavirus

Bill:

Here are the links to the scientific papers and a commentary about the scientific basis of the origins of SARS-CoV-2.

Also this statement from Eddie Holmes

Best regards,

Tony
Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b)(6)
FAX: (301) 496-4409
E-mail: (b)(6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender’s own and not expressly made on behalf of the NIAID by one of its representatives.

On Apr 19, 2020, at 2:21 PM, Bill Gertz <bgertz@washingtontimes.com> wrote:

Katie,

Dr. Fauci on Friday said he would share a scientific paper with the press on the origin of the coronavirus. Can you please help me get a copy of that paper? Thanks in advance.

Bill Gertz
Thanks Greg.
Patty:
Please respond to Dr. Dzau’s questions.
Thanks,
Tony

Patty I had spoken to ASF about using a few slides and he said yes / I will have them done shortly:

- V Dzau: I will begin the session by providing brief (~3 min) opening remarks describing the circumstances of the pandemic. Then, I will introduce the panelists and you will each have 7 minutes to provide remarks. You may use a limited number of slides for illustration. I hope that each panelist will provide their own perspective and speak to the issues proposed below.
- Jeremy Farrar will discuss the global response to the pandemic, drawing from his experience as a global leader, the chair of the Scientific Advisory Group for the WHO's R&D Blueprint and as a member of the Global Preparedness Monitoring Board.
• Tony Fauci will discuss the US pandemic and provide his perspective as a member of the White House Coronavirus Task Force addressing the 2019–20 coronavirus pandemic.
• George Gao will discuss China’s response to the pandemic and lessons learned for the rest of the globe.
• Susan Weiss will discuss the viral characteristics of SARS COV2, insights into its pathobiology, immunity and development of a pan-CoV antiviral.
• Richard Hatchett will discuss the development of new vaccines and treatments against COVID-19.
• Sanjay Gupta will comment on the health system response to the pandemic and challenges related to communication and public engagement in responding to COVID-19.

We need to discuss tomorrow on our daily meeting/call – do you want to do slides.

Again this event is on a Saturday and is tentative as we do not know when the TF meeting will be scheduled that day.

So – if you can do it - will you use slides?
So if you can't do this – do you want a surrogate and who?

I will make sure David is on board for zoom.

---

From: Dzau, Victor J. <VDzau@nas.edu>
Sent: Sunday, April 19, 2020 3:11 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Cc: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Mun, Jenny <JLMun@nas.edu>
Subject: IMPORTANT

Dear Patty,

I hope this finds you well. I know how terribly busy Tony is and I hate to trouble him, however, the NAS Annual Meeting panel on COVID-19 is less than a week away and my team needs answers to the questions below. Can you call this to his attention or assist him in providing the signed form and requested information? We hope to have this by Tuesday (4/23) morning, if possible.

- Please provide a cell number where you can be reached in case you do not connect in time (if you prefer, you can provide the number of your assistant if they will be able to reach you directly by cell or at home).

- Will you have slides to display during your talk?

- Are you able to use Zoom 'share your screen' to show the slides directly during your talk or do you need someone from NAS to show your slides for you?

- Will you need a test session with our Zoom techs? Please let me know as soon as possible as staff are available to hold training sessions through Monday, April 20 (9 AM to 5 PM EDT).

- If you would like to promote your participation in our meeting on social media, please let me know the contact of your social media contact from your institution.

Finally, because this is going to be a remote meeting, we would like panelists to log into Zoom 30 minutes before the session starts – that is at 1:30 pm ET to go over the technology and any last minute speaker prep. So far, more than 800 Academy members have registered for the meeting and there will be additional members of the public and possibly the press tuning in.

Best,
Victor
From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 19 Apr 2020 03:29:42 +0000
To: Peter Daszak
Subject: RE: Thank you for your public comments re COVID-19’s origins

Peter:
Many thanks for your kind note.
Best regards,
Tony

From: Peter Daszak
Sent: Saturday, April 18, 2020 9:43 PM
To: Morens, David (NIH/NIAID) [E]
Cc: Stemmy, Erik (NIH/NIAID) [E]; Erbeiding, Emily (NIH/NIAID) [E]; Aleksei Chmura
Subject: Thank you for your public comments re COVID-19’s origins
Importance: High

Tony (cc’ing David so that you might pass this on to Tony once he has a spare second)

As the PI of the R01 grant publicly targeted by Fox News reporters at the Presidential press briefing last night, I just wanted to say a personal thank you on behalf of our staff and collaborators, for publicly standing up and stating that the scientific evidence supports a natural origin for COVID-19 from a bat-to-human spillover, not a lab release from the Wuhan Institute of Virology.

It’s been a very hard few months as these conspiracy theorists have gradually become politicized and hardened in their stance. Especially because the work we’ve been doing in collaboration with Chinese virologists has given us incredible insight into the risks that these viruses represent, so that we can directly help protect our nation from bat-origin coronaviruses. We’re fighting to keep the communications open with our Chinese colleagues, so that we can better address future pandemics like COVID-19.

From my perspective, your comments are brave, and coming from your trusted voice, will help dispel the myths being spun around the virus origins.

Once this pandemic’s over I look forward thanking you in person and let you know how important your comments are to us all.

Cheers,
Peter
Peter Daszak  
_President_  

EcoHealth Alliance  
460 West 34th Street  
New York, NY 10001  
USA  

Tel.: [Redacted]  
Website: [www.ecohealthalliance.org](http://www.ecohealthalliance.org)  
Twitter: [@PeterDaszak](https://twitter.com/PeterDaszak)  

_EcoHealth Alliance develops science-based solutions to prevent pandemics and promote conservation_
Followup email from Jake Tapper.

Robert W. Eisengr, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (6)(6)
Email: (6)(6)

From: Jake Tapper
Sent: Saturday, April 18, 2020 4:53 PM
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Re: cotton swabs

Got it
Thanks

On Sat, Apr 18, 2020 at 4:52 PM Fauci, Anthony (NIH/NIAID) [E] wrote:

This is what I was referring to. They are not ready for prime time, since they have to get the right media and wrapping.

Subject: Qtip announcement


Coronavirus (COVID-19) Update: FDA, Gates Foundation, UnitedHealth Group, Quantigen, and U.S. Cotton Collaborate to Address Testing Supply Needs
The U.S. Food and Drug Administration announced a further expansion of COVID-19 testing options through the recognition that spun synthetic swabs — with a design similar to Q-tips — could be used to test patients by collecting a sample from the front of the nose.

As part of this effort, U.S. Cotton, the largest manufacturer of cotton swabs and a subsidiary of Parkdale-Mills, developed a polyester-based Q-tip-type swab that is fully synthetic for compatibility with COVID-19 testing. Harnessing its large-scale U.S.-based manufacturing capabilities, U.S. Cotton plans to produce these new polyester swabs in large quantities to help meet the needs for coronavirus diagnostic testing.

“This action today demonstrates the ingenuity that results from the FDA working in partnership with the private sector. The Trump Administration has been working side-by-side with our industry partners to fight this pandemic, and today is a great example of that work. We appreciate work by UnitedHealth Group, Quantigen, and the Gates Foundation to perform and support the clinical studies necessary for this advancement. We also want to acknowledge U.S. Cotton’s efforts to manufacture a new type of swab for COVID-19 testing that can be produced at scale. We appreciate the work of these collaborators to consider how these test supplies could be broadly distributed to meet not only the testing needs of the United States but also global needs around the pandemic. All of these actions by these American organizations will help continue to expand our testing capability,” said FDA Commissioner Stephen M. Hahn, M.D.

This finding that spun synthetic swabs could be used for COVID-19 testing is based on results from a clinical investigation that represents a collaboration between the FDA, UnitedHealth Group, the Gates Foundation, and Quantigen. The type of testing at the front of the nose used in this study is notable because it allows self-collection by patients thereby limiting exposure of healthcare providers; it is more comfortable for patients and it can be performed by a swab that is more readily available and manufacturable at scale.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4409
FAX: (301) 496-4409
E-mail: (b)(6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.
LARRY,

I have gone over the manuscript and have made a number of edits that are tracked into the attached document. Please take a look, accept the changes (unless you have issues with them), add the references and then let us discuss next steps, i.e. add or not Francis to authors and where in the order.

JOHN,

Please also give it another good look.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4409
FAX: (301) 496-4409
E-mail: (301) 496-4409
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.
Please see me about this on Monday. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4409
E-mail:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Kathy Ireland
Sent: Tuesday, April 7, 2020 4:56 PM
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: You are a Hero

Dear Dr. Fauci,

Thank you for everything you're doing for America and the world. I'm writing to you today, rather than calling, because it's impossible to imagine the degree to which leading science during this COVID-19 pandemic is impacting your life and your family. Please know, that your wisdom and passion brings so much comfort to millions, including our family and me, specifically. You may recall from our previous talks, that What a vicious virus, Dr. Fauci ... unlike anything I've ever seen.

In addition to my work as Ambassador for the Elizabeth Taylor AIDS Foundation, it is also an honor and responsibility to serve as International Youth Chair for the National Pediatric Cancer Foundation. In that position, people approach with questions for our government that I am uncomfortable giving opinions on in ignorance. So reluctant to bother you - I'm seeking to learn who at the NIH I should bring this to?

The question comes from my associate...
Thank you so much for all that you do.

Always,

Kathy
This article about my relationship with Shelly Wolff is worth reading.

Hi tony:

Glad this worked out. Wonderful article. Great tribute to both you and Shelly. But the socks in the last picture......

On another note, So when the pandemic is over or when you are down there and want a break, I can put you in touch with him to see the Regis bb goal.

He has been following your career for many years. Very nice fellow.

Thanks for all you are doing Tony, it only sounds like it is getting more and more difficult. But you are doing an amazing job....
So proud of you and that!

Best Bart
Have we decided to set this up. Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender’s own and not expressly made on behalf of the NIAID by one of its representatives.

Jack Curry (broadcaster with the YES Network, which is like MASN, but for the Yankees) is appealing to you as a New Yorker and lifelong Yankees fan for a 10-minute interview via Zoom. Jack covered the Yankees for 22 years at the NYT. The interview would run on YES (largest regional sports network in the country) as the focus of one of the original shows they are producing 3x/week called “YES, WE’RE HERE.” It would be run across all of their social media platforms (reach of over 1M). They would also air clips on the Michael Kay Radio Show (TV play-by-play announcer for the Yankees), which is simulcast on YES and is the highest-rated drive time talk show in New York.

Questions below, including a few at the end about your lifelong baseball fandom. Is this something you’d be willing to do? If so we will seek clearance.

POSSIBLE QUESTIONS
DOCTOR FAUCI, I KNOW YOUR DAYS ARE FILLED WITH OFFERING ADVICE AND COUNSEL TO SO MANY PEOPLE ABOUT THE CORONAVIRUS. WITH THE SOBERING POSITION WE HAVE BEEN IN FOR A WHILE, WHAT WOULD YOUR MOST URGENT MESSAGE TO AMERICANS?

THE PHRASE ‘FLATTENING THE CURVE’ HAS BECOME COMMONPLACE IN OUR VERNACULAR IN RECENT WEEKS. HOW MUCH CLOSER ARE WE GETTING TO FLATTENING THE CURVE?

YOU’VE SAID SEVERAL TIMES THAT THE VIRUS IS THE CLOCK. WHAT IS THE VIRUS TELLING YOU ABOUT THAT TIME FRAME?

AS THE COUNTRY TRIES TO WORK ITS WAY BACK, THERE HAS BEEN SPECULATION ABOUT HOW PROFESSIONAL SPORTS CAN RETURN. WHAT ARE YOUR THOUGHTS ON HOW, FOR INSTANCE, MAJOR LEAGUE BASEBALL WOULD BE ABLE TO START ITS SEASON?

BASEBALL IS A SPORT IN WHICH SHAKING HANDS IS AS COMMON AS BALLS AND STRIKES. NOT JUST IN BASEBALL, OBVIOUSLY, BUT IN LIFE OVERALL, HOW MUCH DO YOU ADVOCATE NOT SHAKING HANDS ANYMORE?

THE NEW YORK TIMES REFERRED TO YOU AS THE EXPLAINER-IN-CHIEF IN COMPLIMENTING YOUR ABILITY TO SPEAK BLUNTLY AND TRUTHFULLY. SO HOW SHOULD AMERICANS PLAN ON BEHAVING AS WE MOVE FORWARD IN THESE UNCERTAIN TIMES?

AND...IF DR FAUCI WAS COMFORTABLE WITH IT, A COUPLE OF QUESTIONS ABOUT HIS BASEBALL FANDOM...

WITH ALL THAT’S HAPPENING AROUND US AND YOUR IMPORTANT ROLE IN IT, IT MIGHT SEEM TRITE TO DISCUSS BASEBALL, BUT I KNOW YOU’VE BEEN A YANKEE FAN FOR MORE THAN 70 YEARS, AND I WOULD LIKE TO ASK YOU A FEW BASEBALL QUESTIONS.

WHEN AND HOW DID YOUR YANKEE FANDOM BEGIN?

YOU WERE A YOUNGSTER WHEN THE YANKEES WON 5 STRAIGHT WORLD SERIES TITLES FROM 1949-1953, THE ONLY TIME THAT’S EVER HAPPENED IN BASEBALL HISTORY. WHAT ARE YOUR MEMORIES OF THOSE YEARS?

HOW HAS YOUR BACKGROUND IN SPORTS HELPED YOU IN YOUR ROLE WITH THE NIAID?

AND, FINALLY, YOU’VE SPOKEN ABOUT HOW NEW YORK IS THE EPICENTER OF THE VIRUS. FOR NEW YORKERS WHO ARE LOOKING FOR SOME LIGHT AT THE END OF THE TUNNEL, WHAT WOULD YOU SAY TO THEM?
Begin forwarded message:

From: "RYAN, Michael J." >
Date: April 27, 2020 at 5:34:56 AM EDT
To: SHOC, Office of the Director-General <DGoffice@who.int>, "Redfield, Robert R. (CDC/OD)"
    "Fauci, Anthony (NIH/NIAID) [E]"
    "Grein, Thomas"
    "Cox, Paul Michael"
    "Schwartlander, Bernhard F."
    "MINHAS, Raman"
    "Conrad, Patricia (NIH/NIAID) [E]"
    "MAHIJOUR, Jaouad"
    "Fall, Ibrahima Seck"
    "Thomas R. Frieden"
    Lynn Banks <lynn.banks@unresolve.org>, "Amadou.SALL"
    "AL-SORBAJI, Farah"
    Robynn Leidig
    "DRURY, Patrick Anthony"
    "Dr VAN KERKHOVE, Maria"
    "POOLE, Marcia"
    "Graaff, Peter Jan"
    "Tarik Mohammed"
Dear colleagues,

Dr Tedros would like to invite you to the next informal discussion about the ongoing 2019 novel coronavirus.

The teleconference will be hosted on **THURSDAY, 30 April at 14:30 CET** and Zoom details are copied below.

If you experience any technical difficulties joining this conference call, please contact the WHO HQ EOC operator at: +41227915533
It would be appreciated if you could kindly confirm your participation to Ms Sophia Kabir, email [REDACTED], mobile no. [REDACTED].

The agenda and background documents will be shared ahead of the call.

Best,

Mike

Join Zoom Meeting
https://who.zoom.us/j/[REDACTED]
Meeting ID: [REDACTED]
Password: [REDACTED]
Dial by your location
  +41 43 210 71 08 Switzerland
  +41 43 210 70 42 Switzerland
  0 800 561 252 Switzerland Toll-free
  0 800 002 622 Switzerland Toll-free
  +1 253 215 8782 US (Tacoma)
  +1 213 338 8477 US (Los Angeles)
  888 475 4499 US Toll-free
  877 853 5257 US Toll-free
  +33 7 5678 4048 France
  +33 1 7095 0350 France
  0 800 944 049 France Toll-free
  0 800 940 415 France Toll-free
Meeting ID: [REDACTED]
Find your local number: https://who.zoom.us/u/aeFZfwUgUc
Join by SIP
  [REDACTED]@zoomcrc.com
Jeff:

Well-deserved recognition of your fine work.  Keep it up.
Best regards,
Tony

From: Duchin, Jeff
Sent: Sunday, April 26, 2020 11:58 PM
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: High Praise

Tony - in a recent shoddy "investigative journalism" piece about our work here in Seattle (https://www.seattletimes.com/seattle-news/times-watchdog/why-the-seattle-sounders-game-went-on-despite-coronavirus-emergency/) the reporter referred to me as being to the Seattle area what Anthony Fauci would become to the country. So despite the crappy reporting he bestowed upon me the highest of praise and reminded me again of the incredible service you are doing for our country. Hang in there and take care of your self. We need you. Jeff

Why the Seattle Sounders game March 7 went on despite coronavirus emergency

As virus fears grew, public officials and sports execs debated health risks — and PR messages — but let 33,000 into a March 7 Sounders match. At what cost?

www.seattletimes.com

Jeffrey S. Duchin, MD (he/him)
Health Officer and Chief, Communicable Disease Epidemiology & Immunization Section
Public Health - Seattle and King County
Professor in Medicine, Division of Infectious Diseases, University of Washington
Adjunct Professor, School of Public Health
401 5th Ave, Suite 1250, Seattle, WA 98104
Tel: (206) 296-4774; Direct (b) (6); Fax: (206) 296-4803
E-mail: (b) (6)
I suggest that we discuss this with other stakeholders.

From: Shapiro, Neil (NIH/OD) [E]  
Sent: Sunday, April 26, 2020 10:32 PM  
To: Collins, Francis (NIH/OD) [E]; Tabak, Lawrence (NIH/OD) [E]; Fauci, Anthony (NIH/NIAID) [E]; Johnson, Alfred (NIH/OD) [E]  
Subject: NIAID facilities in the CARES Act spend plan  
Importance: High

Francis and Tony,

I have been working to get OMB/ASFR clearance for the 3rd Supplemental spend plan, and have encountered a hitch with OMB concerning the VRC/RML proposal. They say they

I raised the issue to Norris, and he asked me to

(b)(5) Thanks,

Neil
Yes, please.

Want me to call?

I think it would be very helpful, I see no downside...

If it would be helpful, I'd be glad to do the outreach to Holden Thorp - Tony and I can discuss.

Francis

All good options. Let us go with Science first. If they do not want it, I am certain that Science Translational Medicine will take it. I will discuss with Francis and John.
In looking at NEJM, they have had 4 COVID-19 perspectives in last 6 weeks, and they may have impacted their thinking.

Agree with talking to editors. If interest in Science or Nature, suggestions below.

Priscilla Kelly, editor at science emailed me a while about their interest in papers. So if interest in Science, we could check with her.

If Nature, Ursula Weiss.

John

From: Corey MD, Larry  
Sent: Saturday, April 25, 2020 5:50 PM  
To: Collins, Francis (NIH/OD) [E]  
Cc: Fauci, Anthony (NIH/NAID) [E]  
Subject: Re: New England Journal of Medicine 20-13479

You and Tony decide. Science or Nature accomplish the same but it seems we need a discussion with the editor first to explain the importance of the manuscript.

Sent from my iPhone

On Apr 25, 2020, at 2:18 PM, Collins, Francis (NIH/OD) [E] wrote:

Very surprised.

Do you want me to push back?

Francis

From: Corey MD, Larry  
Sent: Saturday, April 25, 2020 3:55 PM  
To: Fauci, Anthony (NIH/NAID) [E]; Mascola, John (NIH/VRC) [E]  
Cc: Collins, Francis (NIH/OD) [E]  
Subject: RE: New England Journal of Medicine 20-13479

A do have to say I am surprised, but ok
Let us discuss next steps:

Begin forwarded message:

From: New England Journal of Medicine  
<onbehalfof@manuscriptcentral.com>
Date: April 25, 2020 at 12:31:26 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" <afauci@niaid.nih.gov>
Subject: New England Journal of Medicine 20-13479
Reply-To: "editorial@nejm.org" <editorial@nejm.org>

Dear Dr. Fauci,

I am sorry to inform you that your submission, "A Strategic Approach to Successful COVID-19 Vaccine Development," has not been accepted for publication in the Journal. It was evaluated by members of our editorial staff. After considering its focus, content, and interest, we made the editorial decision not to consider your submission further. We are informing you of this promptly so that you can submit it elsewhere.

Thank you for the opportunity to consider your submission.

Sincerely yours,

Eric Rubin, M.D., Ph.D.
Editor-in Chief

New England Journal of Medicine
10 Shattuck Street
Boston, MA 02115
(617) 734-9800
Fax: (617) 739-9864
http://www.nejm.org
Adrian:  

Thank you for your note. Sorry that I took a few days to get back to you, but I have been swamped. It is good to know of your work on the chimpanzee adenoviral vectors. The biosafety classification of viral vectors in the U.S. is within the purview of the CDC, and so I have copied CDC Director Bob Redfield on this e-mail. He would be able to point you in the right direction.  

Best regards,  

Tony

Dear Dr. Fauci,

Thank you for your consideration of this at an exceptionally busy time.
Yours sincerely

Adrian Hill

Professor Adrian V. S. Hill
Director, The Jenner Institute
Nuffield Department of Medicine
University of Oxford
Old Road Campus Research Building
Oxford OX3 7DQ.

Tel: + (b) (0)
Email: (b) (0)
Please see me or give me a call about this. Thanks.

Hi Dr. Fauci,

Jon Yewdell suggested I contact you directly to expedite a briefing on the new county-level models that our center, PolicyLab, at CHOP, will be releasing tomorrow. He shared with us your note below about including Ambassador Birx and Bob Redfield as well. We'd be happy to do so, and had been in touch with Ambassador Birx last week. We have also stayed in contact with the analytics team led by Irum Zaidi and Chuck Vitek. I am also tasked to Governor Wolf's crisis team in Pennsylvania and shared the data with the Governor today.

Let us know next steps for arranging a video conference. Will arrange our schedule at your convenience. Will have Drs. Paul Offit, Greg Tasi, and Jing Huang join from our team.

Best,

Dave

David Rubin, MD MSCE
Director of Population Health Innovation
Director of PolicyLab

Children's Hospital of Philadelphia
Office: (b) (6)
Cell: (b) (6)
www.policyleb.chop.edu | @PolicyLabCHOP
From: "Yewdell, Jon (NIH/NIAID) [E]"
Date: Tuesday, April 21, 2020 at 8:55 PM
To: "Rubin, David M"  
Cc: Paul Offit  
Subject: <no subject>

David,
At this point, I think it is best to contact Tony directly. He’s at
Good luck!
jon
Jonathan Yewdell MD, PhD
Chief, Cellular Biology Section
Laboratory of Viral Diseases
NIAID, NIH

Truth Wins: A Practical Guide to Succeeding in Biomedical Research
free eBook download of my book

Link to Ohio State Science Sunday video on scientific method

From: Rubin, David M <bicasr@hms.harvard.edu>
Sent: Tuesday, April 21, 2020 8:43 PM
To: Yewdell, Jon (NIH/NIAID) [E]
Cc: Offit, Paul  
Subject: FW: Heads up from Paul Offit and David Rubin on policy memorandum to reopen economy

Hi Jon,

Paul forwarded me your email back to him. Our team would be happy to present to him, Ambassador Birx, and Bob Redfield. We have shared the models with Governor Wolf in Pennsylvania today, and they are informing strategy here. The 260 county models will post to our PolicyLab website tomorrow. Of
note, Paul and I had spoken to Ambassador Birx in the last couple of weeks, and we have been in contact with Irum Zaidi, Chuck Vitek, and the analytics team.

Let us know how would be best to set up a group webinar to present the information. Or feel free to connect us directly with their schedulers. Think the models illustrate the low margin of error in the large cities for resurgence risk, even as other less densely populated counties may be tolerant to reopening strategies.

Dave

David Rubin, MD MSCE
Director of Population Health Innovation
Director of PolicyLab
Children’s Hospital of Philadelphia
Office: (b) (6)
Cell: (b) (6)
www.policylab.chop.edu | @PolicyLabCHOP

Children’s Hospital of Philadelphia
Professor of Pediatrics
Perelman School of Medicine
University of Pennsylvania

From: Paul Offit
Date: Tuesday, April 21, 2020 at 5:46 PM
To: "Rubin, David M"
Subject: Fw: Heads up from Paul Offit and David Rubin on policy memorandum to reopen economy

Tony has seen our memo. His response is below.

From: Yewdell, Jon (NIH/NIAID) [E]
Sent: Tuesday, April 21, 2020 5:45 PM
To: Offit, Paul
Subject: FW: Heads up from Paul Offit and David Rubin on policy memorandum to reopen economy
Tony never ceases to amaze me....

See immediate reply below

Jonathan Yewdell MD, PhD
Chief, Cellular Biology Section
Laboratory of Viral Diseases
NIAID, NIH

Truth Wins: A Practical Guide to Succeeding in Biomedical Research
free eBook download of my book

Link to Ohio State Science Sunday video on scientific method

From: Fauci, Anthony (NIH/NIAID) [E] (b)(6)
Sent: Tuesday, April 21, 2020 5:06 PM
To: Yewdell, Jon (NIH/NIAID) [E] (b)(6)
Cc: Shaffer, Meredith (NIH/NIAID) [E] (b)(6); Conrad, Patricia (NIH/NIAID) [E] (b)(6); Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: Heads up from Paul Offit and David Rubin on policy memorandum to reopen economy

Jon:

Thanks for the note. It would be even better if they could present not only to me, but to Deb Birx and Bod Redfield.
Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Yewdell, Jon (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, April 21, 2020 4:29 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Shaffer, Meredith (NIH/NIAID) [E] (b) (6)
Subject: Heads up from Paul Offit and David Rubin on policy memorandum to reopen economy

Tony,

Paul and David asked me to pass this on to you.

Forwarded message from David:

"I think the time has come, with our models on 260 counties across the country releasing in the next 48 hours, to offer Tony Fauci, and potentially other task force members, a preview of the work. Our models have incorporated local area differences due to weather, population and social distancing. They reveal that the large, densely populated cities will struggle to re-open, and are not well aided by weather effects given their density. However, in less densely populated areas, in which case counts are lower, weather has been a mitigating factor. These latter counties may
have better success when they re-open assuming they are smart about workplace safety and have testing and surveillance strategies in place”

Dave

David Rubin, MD MSCE
Director of Population Health Innovation
Director of PolicyLab
Children’s Hospital of Philadelphia
Office: (5) (6)
Cell: (6) (6)
www.policylab.chop.edu | @PolicyLabCHOP

Children’s Hospital of Philadelphia
Professor of Pediatrics
Perelman School of Medicine
University of Pennsylvania
Thanks, Neal.
Best regards,
Tony

Dear Tony

'Forwarding to you at the request of two colleagues, experts in anti-complement therapies.

Thanks, and 'stay healthy.

Neal

Hi Neal,

I hope all is well and you are staying healthy.

Could you please bring us in contact with Antony Fauci to see if he can help our program?

All the best and Stay Healthy

John
Dear Dr. Fauci,

dear Dr. Coomes,

thank you for your reply from 13 April with the notice that the information has been shared with NIAID’s COVID-19 research team.

Has the project already been initially evaluated by the team?

Are there any questions or need for additional information?

- I have summed up the relevant data regarding the use of proteasome inhibitors for treatment of COVID-19 patients with acute lung and systemic organ failure in a position paper, please find a preview draft attached.

- With regard to currently ongoing trials with monoclonal antibodies against the IL-6 receptor, i.e. tocilizumab or sarilumab: These approaches go into the same direction as the present suggestion, however, inhibition of NF-κB by proteasome inhibitors could provide the unique potential to inhibit the release of multiple cytokines simultaneously, in particular strongly pro-inflammatory cytokines including IL-1, IL-6, TNFα and chemokines, such as MIP-1 and CXCL1.

- This simultaneous inhibition of multiple cytokines/chemokine seems to be advantageous compared to single target approaches (as with the mAb) to compensate for redundant and synergistic effects of multiple cytokines released during highly pathogenic CoV or H5N1 infection.

Looking forward to hearing from you.

Kind regards,

Ralf
Mit freundlichen Grüßen / Kind regards

Dr. Ralf Kircheis
Director R&D
Research & Development

Mail: RKircheis@syntacoll.de
Phone: +49 9441 686048

Von: Coomes, Stephanie (NIH/NIAID) [E] (b)(6) (b)(6)
Gesendet: Montag, 13. April 2020 02:37
An: Kircheis Dr. Ralf <RKircheis@syntacoll.de>
Betreff: RE: Inhibit cytokine storm in COVID-19 patients by Velcade Bortezomib

Dear Dr. Kircheis,

Thank you for your recent email to Dr. Anthony Fauci. Your message was forwarded to the Division of Microbiology and Infectious Diseases (DMID) at the National Institute of Allergy and Infectious Diseases (NIAID). As a member of DMID's Office of Scientific Coordination and Program Operations, I am pleased to respond.

I want to thank you for reaching out to share this information and let you know that your message has been shared with NIAID's COVID-19 research team.

Sincerely,
Stephanie

Stephanie M. Coomes, Ph.D.
Health Scientist Administrator
Office of Scientific Coordination and Program Operations
Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases
National Institutes of Health
5601 Fishers Lane, Room 7C68
Rockville, MD 20892

Disclaimer: The information in this email and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the originally intended recipient. If you have received this email in error, please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of NIAID by one of its representatives.
Inhibition of cytokine storm in COVID-19 patients with acute respiratory distress syndrome by PROTEASOME INHIBITORS e.g. Velcade (Bortezomib)

Dear Dr. Fauci,

dear Madams/Sirs,

I want to bring to your attention some potentially important experimental data and a new proposal for treatment of COVID-19 patients with acute respiratory distress syndrome and organ failure. Sorry for the broad distribution but I wanted to make sure that my message reaches you.

Similarly as has been described earlier for SARS-CoV, MERS-CoV (Chanpananavar & Perlman, 2017), H5N1 and some heavy H1N1 Influenza A infections, also COVID-19 patients have been reported to show significantly increased systemic cytokine release (i.e. cytokine storm), particularly those patients with lung failure or systemic organ failure (Chao Lin Huang et al. Lancet vol 395, 2020, ref 1).

Previous studies at Virologik GmbH, Eriangen, Germany, in collaboration with the Friedrich-Loeffler-Institut, Tuebingen, Germany have shown, that H5N1 (or alternatively LPS)-induced Cytokine storm in vivo can be inhibited by application of Proteasome Inhibitors (E. Haasbach et al, Antiviral Res. 91, 2011, ref. 2), via the inhibition of translocation of the NF-κB transcription factor to the nucleus (see Fig. below). The mechanism of NF-κB inhibition by proteasome inhibitors is well described, and works via the inhibition of the proteasomal degradation of the cytosolic inhibitor IκB, this way keeping NF-κB bound in the cytosol and thereby inhibiting the otherwise induced (by cytokine or LPS- or RNA virus) translocation of NF-κB to the nucleus where it would initiate the transcription of many cytokines. This effect of proteasome inhibitors seems to work in most cell types, we could demonstrate this effect in several different cell types (including macrophages) after stimulation with TNFa in vitro and in H5N1 (or LPS) treated mice in vivo (see manuscript and Figs. attached).

Inhibition of NF-κB by proteasome inhibitors provides the unique potential to inhibit the release of many cytokines simultaneously, in particular strongly proinflammatory cytokines IL-1α, IL-6, TNFa, MIP-1β...) (whereas some other cytokines involved in antiviral immune response, such as IFNy probably seem to be not/less affected (because of different transcription pathway).
Importantly, beside the anti-inflammatory activity, proteasome inhibitors showed also significant anti-fibrotic activity (Lueftengger et al., manuscript and figs attached), which may be also important in the treatment of COVID-19 patients with heavy lung disease.

Furthermore, there have been several publications showing that in particular early phases of the replication cycle of Corona virus seem to be dependent on interaction with the ubiquitin-proteasomal system (UPS) of the host cell, and were effectively inhibited by selective 20S proteasome inhibitors (such as Velcade) (Wang et al. Virology J 2010, 7:99 (ref. 3); M. Raaben et al. J. Virology, 84(15), 2010, ref. 4).

There are several registered proteasome inhibitors (Bortezomib (Velcade®) e.g. produced by Millennium Pharmaceuticals (i.e. Takeca Oncology); Carfilzomib (Kyprolis®), Ixazomib (Ninlaro®)) for treatment of multiple myeloma and Mantel cell lymphoma, i.e. there are registered drugs with well known side effects available to be tested in small clinical studies for evaluation of their therapeutic efficacy in COVID-19 patients with heavy lung disease and other organ failure. Noteworthy; in contrast to the chronic oncological indications where up to 8 treatment cycles (and sometimes even more) are applied, it seems plausible that just one or two treatment cycles of proteasome inhibitors might be sufficient to downregulate the cytokine storm in COVID-19 patients, which would be associated also with much lower side effects.

Early first experience on efficacy could be gained from compassionate use applications in heavily ill COVID-19 patients very quickly. Beside the registered application forms, i.e. infusions, probably also inhalative application should be tested as well, because it may be better suited to reach the respective target cells in the lung, i.e. alveolar epithelial cell and alveolar macrophages. There are multiple inhalative devices available, e.g. the Handyhaler by Boehringer Ingelheim used for Spiriva (for COPD treatment).

Although there are still many open questions, the potential to control the cytokine storm-induced heavy lung and other organ failure by using already registered drugs, i.e. proteasome inhibitors may be a real chance to get an additional treatment option, hopefully decreasing the cases necessary for artificial aeration.

Please forward this mail to the colleagues you consider relevant for evaluation, discussion and consideration for your clinical strategy for COVID-19.

Please let me know if additional informations are necessary.

To my person: I have MD PhD degree and have many years experience in pharmaceutical development (Boehringer Ingelheim), Biotech (Igeneon, Aphon, Virologik GmbH) (for reference see also PubMed Kircheis r) currently leading R&D activities at Syntacoll (part of Innocoll). I am providing this information personally in order to help to find a treatment for COVID-19 patients.

Looking forward to getting feedback from you,

With kind regards,

Ralf Kircheis (MD PhD)

rkircheis@syntacoll.de
Antiviral activity of the proteasome inhibitor VL-01 against influenza A viruses.

Haasbach E¹, Pauli EK, Spranger R, Mitzner D, Schubert U, Kircheis R, Planz O.

Abstract

The appearance of highly pathogenic avian influenza A viruses of the H5N1 subtype being able to infect humans and the 2009 H1N1 pandemic reveals the urgent need for new and efficient countermeasures against these viruses. The long-term efficacy of current antivirals is often limited, because of the emergence of drug-resistant virus mutants. A growing understanding of the virus-host interaction raises the possibility to explore alternative targets involved in the viral replication. In the present study we show that the proteasome inhibitor VL-01 leads to reduction of influenza virus replication in human lung adenocarcinoma epithelial cells (A549) as demonstrated with three different influenza virus strains, A/Puerto Rico/8/34 (H1N1) (EC50 value of 1.7 μM), A/Regensburg/D6/09 (H1N1v) (EC50 value of 2.4 μM) and A/Mallard/Bavaria/1/2006 (H5N1) (EC50 value of 0.8 μM). In in vivo experiments we could demonstrate that VL-01-aerosol-treatment of BALB/c mice with 14.1 mg/kg results in no toxic side effects, reduced progeny virus titers in the lung (1.1 ± 0.3 log10 pfu) and enhanced survival of mice after infection with a 5-fold MLD50 of the human influenza A virus strain A/Puerto Rico/8/34 (H1N1) up to 50%. Furthermore, treatment of mice with
VL-01 reduced the cytokine release of IL-α/β, IL-6, MIP-1β, RANTES and TNF-α induced by LPS or highly pathogen avian H5N1 influenza A virus. The present data demonstrates an antiviral effect of VL-01 in vitro and in vivo and the ability to reduce influenza virus induced cytokines and chemokines.

Copyright © 2011 Elsevier B.V. All rights reserved.

PMID:21777621
DOI:10.1016/j.antiviral.2011.07.006
[Indexed for MEDLINE]

Mit freundlichen Grüßen / Kind regards

Dr. Ralf Kirchels
Director R&D
Research & Development

Mail: RKirchels@syntacoll.de
Phone: +49 9441 686048

Syntacoll GmbH, Donaustrasse 24, D-93342 Saal a. d. Donau
Telm: +49 9441 / 68 60 0, Fax: +49 9441 / 68 60 30
Handelsregister: Amtsgericht Regensburg - HRB 1612
US-I.D.Nr. DE 128580796
Geschäftsführerin: Dr. Alexandra Dietrich

Unsere Hinweise zum Datenschutz, insbesondere zu den Ihnen zustehenden Rechten, finden Sie unter www.syntacoll.de/datenschutz
From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 00:40:50 -0000
To: Xizhong, Cui (NIH/CC/CCMD) [E]
Subject: RE: remdesivir and Present’s words on disinfectant

Brian:
Thank you for your note.  

Best regards,
Tony

From: Xizhong, Cui (NIH/CC/CCMD) [E]
Sent: Sunday, April 26, 2020 8:36 PM
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: remdesivir and Present’s words on disinfectant

Dear Dr. Fauci,

I am an investigator in CCMD, CC, National Institutes of Health, I am studying coronavirus infection in animal models on preclinical treatment. I was a doctor when I was in China, now I am just a preclinical investigator on infectious diseases.

Best wish to you and be safe. Thanks your efforts to all Americans!!
Agree.

On Apr 26, 2020, at 6:38 PM, Folks, Greg (NIH/NAID) [E]
<unnamed> wrote:

I think Hilary is closest to this and should get the assignment.

---

Greg and team:

Let us discuss.

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4409
FAX: (301) 496-4409
E-mail: unnnamed

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.
Greetings Dr. Fauci:

Thank you for agreeing to participate as the keynote speaker for the Keystone eSymposia: Vaccinology in the Age of Pandemics: Strategies Against COVID-19 & Other Global Threats, a virtual conference which will be held on, Monday, June 15 and Tuesday, June 16, 2020.

Understanding how busy you are right now, we would like to make this process as easy as possible. We are hoping to receive pre-recorded talks by Monday, May 18. Please keep us apprised on your timeline and we will work with your schedule. Here are the details on next steps.

Next Steps:

- **Keynote Talk Title:** Transforming Vaccinology: COVID-19 Emergency and Considerations for the Next Decade
  - Please review your talk title and return any changes. Changes can be made up to two-weeks prior to the event.

- **Please follow this link to upload your talk recording, by Monday, May 18.** Click [here](#) to learn more about recording your presentation. Our media team can assist you with recording on your personal computer.
  - Similar to the face-to-face conference, we envision approximately 50-60 minutes for the keynote lecture.

For questions about the scientific programming of this meeting, please contact Dr. Rappuoli at rino.r.rappuoli@csk.com and I will serve as the administrative/logistics contact at KristinaH@KeystoneSymposia.Org.

Best,
Kristina

Krisitina H. Richardson, MS
Scientific Advisory Board Coordinator
Administrative Assistant: CSO & Global Development

<image001.png>
KEystone SYMPOSIA* on Molecular and Cellular Biology

Accelera%ing Life Science Discovery

INCLUDE

DIVERSITY IN THE SCIENTIFIC WORKFORCE
Gayle and so I would like to do it if they clear it.

On Apr 26, 2020, at 7:08 PM, Conrad, Patricia (NIH/NIAID) [E] wrote:

You sent this to me on Friday but we have not had a chance to discuss.

Please advise if you want to do this – again, adding others here as well.

-p

Have we discussed this already? Gayle
Dear Tony,

I have always felt reassured when the good Dr. Fauci speaks, and now more than ever. As an American, a former colleague, a long-time admirer and student of your wisdom – thank you. We are all safer because of you, and the world will be a better place because of you. Again.

As you know, I am now leading the ONE Campaign. We’ve been quite active with the ONEWorld Campaign, dedicated to the fight against this newest virus, and focused on Africa. We’ve made some progress on debt, and next up is a focus on ensuring that a vaccine, when it comes, is available to everyone.

One of the things we want to do is educate people, in all of the places we work. It won’t surprise you that of particular urgency amongst our partners in Africa is that facts and information get to people across the continent, but we also know that more facts are needed everywhere. So next month we are going to launch #PassTheMic, where every day for 19 days we will ask a celebrity to turn his or her social media channels over to an expert on COVID-19 for one day. So Julia Roberts might turn her Twitter account to you to talk about the critical elements needed to flatten the curve and slow the spread. Or Idris Elba could give up his Instagram to the head of the African CDC so that he can illustrate the impact COVID-19 will have across Africa and what that means for the rest of the world.

We know artists want to be helpful right now, but that it is hard to know what to do. And we know there are experts like you out there who have the answers. We’ve thought about this a lot at ONE and wanted to do something we felt would truly have an impact. As we look ahead we know COVID-19 does not know borders and until it is beaten everywhere we are not in the clear. We need a global response plan and we need it now. By turning over their platforms for the day, celebrity influencers will be donating one of their biggest assets – their followers – to YOU, giving you the platform you need (and we all need) to tell the world why a global response is critical. Because none of us are safe until all of us are safe.
We will work with each expert/celebrity pair to personalize the content to our and our celebrity partners’ audiences – in North America, Europe and Africa, and help create content that both parties are happy with. We are now confirming our talent partners, and so far are getting a terrific response.

We know you’re a busy man, so we’ve planned it so that the amount of time on your end would be minimal. But the impact would be maximal.

I’m attaching more information about the campaign. Please let me know what you think and if you have questions. Ideally we would like to get this off the ground in early May, so are hoping to confirm folks by April 28th at the latest. Our team will be in touch with your office to follow up.

Thanks as always for everything you do. All my best to you, Gayle

Gayle Smith | President & Chief Executive Officer | ONE.ORG | Twitter | Facebook | Instagram

ONE is a global movement campaigning to end extreme poverty and preventable disease by 2030 so that everyone, everywhere can lead a life of dignity and opportunity.

<PassTheMic Expert Outreach.pdf>
From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 21:50:57 +0000
To: Broas, Timothy
Cc: Grady, Christine (NIH/CC/BEP) [E]
Subject: RE: Greetings

Tim:
Thank you for your kind note. It was great to hear from you. I hope that all is well with you and your family and that we get a chance to reconnect when the situation begins to return to some form of normality.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted]
FAX: (301) 496-4409
E-mail: [redacted]
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Broas, Timothy <timothy.broas@bcplaw.com>
Sent: Thursday, April 23, 2020 10:26 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted]
Subject: Greetings

Dear Tony:

It's been a long time. Honestly, I can't remember when we last saw each other. I recall that wonderful day we went to the Nats game together, although I cannot remember who else came with us. And of course I will always remember when you came to my Partners in Health fundraiser and introduced Paul Farmer. I will never forget your speech (and neither will Paul!). Once [redacted] I apologize for dropping out of touch.
Those events were so many years ago. Yes? So much has happened and changed since then, and now, seeing you and listening to your wise words and advice every day, I am reminded that we need to reconnect, when it's safe and you have time. We need to catch up on! I have been meaning to write to you or call you, but I had misplaced your email address and phone numbers. I hope this address works and this message reaches you.

Meantime, thank you for your service to our country, indeed the world. You have been a solid, wise, steady voice, Tony, and, despite all the naysayers and fools on social media, you have earned the respect of billions of people. I am very proud of you, and am humbled and honored that I can call you my friend.

I hope you and your family are well, and staying safe. The Broes family is doing well, thanks in no small part to your daily advice and objective analysis. Thank you! Please let me know if there is anything I can do for you or your family.

Looking forward to seeing you on the other side of this, and having a good catch up. Who knows, maybe a Nats game?

Best regards,

Tim

AMBASSADOR (RET) TIMOTHY M. BROAS

timothy.broas@bclplaw.com

BRYAN CAVE LEIGHTON PAISNER LLP:
1155 F Street NW, Washington, DC 20004-1357

bclplaw.com

COVID-19 / CORONAVIRUS RESOURCES

This electronic message is from a law firm. It may contain confidential or privileged information. If you received this transmission in error, please reply to the sender to advise of the error and delete this transmission and any attachments.

We may monitor and record electronic communications in accordance with applicable laws and regulations. Where appropriate we may also share certain information you give us with our other offices (including in other countries) and select third parties. For further information (including details of your privacy rights and how to exercise them), see our updated Privacy Notice at www.bclplaw.com.
From: Gayle Smith <gayle.smith@one.org>
Sent: Thursday, April 23, 2020 1:48 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)
Cc: Tom Hart <tom.hart@one.org>
Subject: Thank you, and...

Dear Tony,

I have always felt reassured when the good Dr. Fauci speaks, and now more than ever. As an American, a former colleague, a long-time admirer and student of your wisdom – thank you. We are all safer because of you, and the world will be a better place because of you. Again.

As you know, I am now leading the ONE Campaign. We’ve been quite active with the ONEWorld Campaign, dedicated to the fight against this newest virus, and focused on Africa. We’ve made some progress on debt, and next up is a focus on ensuring that a vaccine, when it comes, is available to everyone.

One of the things we want to do is educate people, in all of the places we work. It won’t surprise you that of particular urgency amongst our partners in Africa is that facts and information get to people across the continent, but we also know that more facts are needed everywhere. So next month we are going to launch #PassTheMic, where every day for 19 days we will ask a celebrity to turn his or her social media channels over to an expert on COVID-19 for one day. So Julia Roberts might turn her Twitter
account to you to talk about the critical elements needed to flatten the curve and slow the spread. Or Idris Elba could give up his Instagram to the head of the African CDC so that he can illustrate the impact COVID-19 will have across Africa and what that means for the rest of the world.

We know artists want to be helpful right now, but that it is hard to know what to do. And we know there are experts like you out there who have the answers. We’ve thought about this a lot at ONE and wanted to do something we felt would truly have an impact. As we look ahead we know COVID-19 does not know borders and until it is beaten everywhere we are not in the clear. We need a global response plan and we need it now. By turning over their platforms for the day, celebrity influencers will be donating one of their biggest assets – their followers – to YOU, giving you the platform you need (and we all need) to tell the world why a global response is critical. Because none of us are safe until all of us are safe.

We will work with each expert/celebrity pair to personalize the content to our and our celebrity partners’ audiences – in North America, Europe and Africa, and help create content that both parties are happy with. We are now confirming our talent partners, and so far are getting a terrific response.

We know you’re a busy man, so we’ve planned it so that the amount of time on your end would be minimal. But the impact would be maximal.

I’m attaching more information about the campaign. Please let me know what you think and if you have questions. Ideally we would like to get this off the ground in early May, so are hoping to confirm folks by April 28th at the latest. Our team will be in touch with your office to follow up.

Thanks as always for everything you do. All my best to you, Gayle

Gayle Smith | President & Chief Executive Officer | ONE.ORG | Twitter | Facebook | Instagram

ONE is a global movement campaigning to end extreme poverty and preventable disease by 2030 so that everyone, everywhere can lead a life of dignity and opportunity.
Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-2308
FAX: (301) 496-4409
E-mail: anthony.fauci@nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]  
Sent: Sun, 26 Apr 2020 21:36:37 +0000  
To: Lusso, Paolo (NIH/NIAID) [E]  
Subject: RE: Potential treatment breakthrough from Milan

Dear Tony:

I am trying to reach the PI of the study, but on a Sunday afternoon/evening I doubt I will be successful. I should be able to get more information tomorrow morning and pass it on to you, Cliff and Joe Kovacs.

All the best,

Paolo

Paolo Lusso, M.D., Ph.D.
Chief, Section of Viral Pathogenesis
Laboratory of Immunoregulation
Bldg. 10, Rm. 6A11
NIAID, NIH
Bethesda, MD 20892
Thanks, Paolo.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)
To: Fauci, Anthony (NIH/NIAID) [E]

Subject: Potential treatment breakthrough from Milan

Dear Tony:

Congratulations to Brad Pitt for impersonating you! All the best.

Paolo
Please set up an interview as requested below. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-2100
FAX: (301) 496-4409
E-mail: ansfauci@nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Davidson, Joe <joe.davidson@washpost.com>
Sent: Friday, April 24, 2020 12:58 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: (b) (6)
Subject: Washington Post story re: Sammies finalists

Hello Tony,

Congratulations on being a Career Achievement finalist for the Samuel J. Heyman Service to America Medals (Sammies). I'm writing a Federal Insider column about the finalists and would like arrange a telephone interview with you for the story.

My questions include:
Why did you join the federal service?
Is there one example or anecdote that makes you particularly proud of your work?
What do you like most about your job?
What do you like least about your job?
Why would you recommend, or not, your agency and/or the federal government to those seeking career advice?

I know this is an incredibly busy time for you. I appreciate that the life and death issues related to the coronavirus are more important than any award. Nonetheless, I hope you
can spare 10 or 15 minutes for a telephone interview on Tuesday or Wednesday, April 28 or 29. I can also make other days that week work.

Thank you.

Best,

Joe

Joe Davidson, columnist
The Washington Post
1301 K Street, NW
Washington, DC 20071
202.334.6415 – work
(b)6415 – cell
joe.davidson@washpost.com
Twitter: @JoeDavidsonWP
Website: wapo.st/JoeDavidson
Please have her speak with Chris and/or Cliff. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4409
Fax: (301) 496-4409
E-mail: anthonyfauci@nih.gov
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender’s own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b)(6)
Sent: Friday, April 24, 2020 3:04 PM
To: NIAID COGcore <COGcore@mail.nih.gov>
CC: NIAID OD AM <NIAIDODAM@nih.gov>
Subject: COG - Helen Branswell/STAT request / challenge studies

Helen would like to speak with someone (ASF, Cliff, C Grady?) to discuss current thinking here on challenge studies for COVID-19. Not sure of deadline.

helen.branswell@statnews.com

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.
From: Kristina Horton <kristinah@keystonesymposia.org>
Sent: Friday, April 24, 2020 4:06 PM
To: Fauci, Anthony [NIH/NIAID] [E] (b) (6)
Cc: rino.r.rappuoli@gsk.com; Conrad, Patricia [NIH/NIAID] [E] (b) (6)
Subject: Keynote Speaker- Keystone Vaccinology eSymposia (directions to record & upload talk)

Greetings Dr. Fauci:

Thank you for agreeing to participate as the keynote speaker for the Keystone eSymposia: Vaccinology in the Age of Pandemics: Strategies Against COVID-19 & Other Global Threats, a virtual conference which will be held on, Monday, June 15 and Tuesday, June 16, 2020.

Understanding how busy you are right now, we would like to make this process as easy as possible. We are hoping to receive pre-recorded talks by Monday, May 18. Please keep us apprised on your timeline and we will work with your schedule. Here are the details on next steps.

Next Steps:
• **Keynote Talk Title: Transforming Vaccinology: COVID-19 Emergency and Considerations for the Next Decade**
  - Please review your talk title and return any changes. Changes can be made up to two-weeks prior to the event.

• Please follow this link to upload your talk recording, by **Monday, May 18**. Click here to learn more about recording your presentation. Our media team can assist you with recording on your personal computer.
  - Similar to the face-to-face conference, we envision approximately 50-60 minutes for the keynote lecture.

For questions about the scientific programming of this meeting, please contact Dr. Rappuoli at rino.r.rappuoli@gsk.com and I will serve as the administrative/logistics contact at KristinaH@KeystoneSymposia.Org.

Best,
Kristina

**Kristina H. Richardson, MS**
Scientific Advisory Board Coordinator
Administrative Assistant: CSO & Global Development
+ [ ] (800) 253.0685 | kristinah@keystonesymposia.org

---

**Keystone Symposia**
on Molecular and Cellular Biology
**Accelerating Life Science Discovery**

**INCLUDE**
DIVERSITY IN THE SCIENTIFIC WORKFORCE

PO Box 1630 | Silverthorne | CO 80498 | USA (regular mail only)
160 US Highway 6, Ste. 200 | Silverthorne | CO 80498 | USA (courier only)
970.262.1230 | 800.253.0685 | www.keystonesymposia.org
Visit virtual.keystonesymposia.org to view our digital content.
Steve:

They have contacted me, but have you seen this? I am sure that it is one of many that you see.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Eli J. Sa'idieh
Sent: Friday, April 24, 2020 4:12 PM
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Re: Thank You!

Dear Dr. Fauci,

Hope all is well. Since this crisis has begun, I have been working... (b) (6)

I look forward to your positive response.
Best Regards,

Eli J. Safdieh

From: "Conrad, Patricia (NIH/NIAID) [E]" on behalf of "Fauci, Anthony (NIH/NIAID) [E]"
Date: Thursday, March 19, 2020 at 10:59 AM
To: Eli Safdieh
Subject: RE: Thank You!

Dr. Fauci wanted me to thank you for your note.

Best regards,

Patricia L. Conrad
Hi Dr.,

Hope all is well with you and your family.

You are a symbol of integrity, nationalism, humanity, brilliance and perseverance. God bless you in all that you do for our country, for human beings and society.

We are praying for your success in mitigating and destroying this epidemic!

Best Regards,

Eli J. Safdieh
Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Dieffenbach, Carl (NIH/NIAID) [E] 
Sent: Friday, April 24, 2020 6:13 PM 
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: Documents as discussed

Dr. Fauci,

I feel compelled to let you know directly when ever I talk to or correspond with an IC Director. I know you asked him to reach out. Just closing the loop.

Carl

-----Original Message-----
From: Dieffenbach, Carl (NIH/NIAID) [E] 
Sent: Friday, April 24, 2020 6:11 PM 
To: Singer, Dinah (NIH/NCI) [E]; Sharpless, Norman (NIH/NCI) [E] 
Cc: Fauci, Anthony (NIH/NIAID) [E]; Auchincloss, Hugh (NIH/NIAID) [E]; Erbelding, Emily (NIH/NIAID) [E]; Cassetti, Cristina (NIH/NIAID) [E] 
Subject: Documents as discussed

Dinah and Ned,

It was a pleasure talking to you about what you are considering. As we discussed, here is the NIAID Strategic Plan that was just published, and two models of funding opportunity announcements for you to consider as models. I also think the Cancer Centers have aspects of collaboration, shared facilities, and research focus that you can borrow. So much of what NIAID has built is modeled on the Cancer Centers.
NIAID strategic plan for COVID-19

Current Centers for AIDS Research FOA

This is a very old RFA. I am sending it because it was NIAID's first attempt to build research capacity for the Level 3 and Level 4 pathogens after the Anthrax events. The current versions of the RFAs have been limited competitions and are a less relevant.

With best regards,

Carl

Carl W. Dieffenbach, Ph.D.
Director
Division of AIDS, NIAID
5601 Fishers Lane, Room 8D34
(he, him, his)
Rockville, MD 20852-9831
Phone: (b)(6)
Cell: (b)(6)
Fax: (240) 627-3466

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The NIAID shall not accept liability for any statement made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.
Yes.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b)(6)
FAX: (301) 496-4409
E-mail: (b)(6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Ok to schedule? This is cleared

Hi Jennifer et al: Here are a few questions for Dr. Fauci.

Scientists from the University of Bristol found that the coronavirus has unexpected tendency to large mutations in the spike protein when its grown in monkey cells. This had been seen
before as a virus that was unwilling to mutate. Does this create any concerns about vaccine design and effectiveness?

It now appears that some people who recover from Covid have no antibodies to the SARS-Cov2. What are the possible explanations for this? Has it occurred in other viral diseases? Does it have any implications for the effectiveness of vaccines? Is NIAID investigating this? Is there a possibility that the virus sequesters in cells?

Another feature of coronaviruses appears to be rapidly waning immunity. Has this been seen in any NIAID experiments? What does this suggest about the virus's ability to evade the immune system?

A laboratory at Oxford has suggested that, if all goes well, they may be finished with phase 3 trials in 5000 people by the fall, which could mean as early as September. Does that sound realistic to you?

Some companies are asking regulators to make sure that safety standards are upheld for makers of Covid vaccines, and that corners aren't cut. Is it worth cutting some safety corners to get a Covid vaccine ready for distribution?

How many people should the Moderna vaccine be tested in in phase 3? How long would you expect those trials to take?

Thanks very much, hope we can set this up soon. All best, JL +44 2035 251028

From: [b][6] At: 04/12/20 22:38:36
To: John Lauerman (BLOOMBERG/ NEWSROOM: )
Cc: [b][6],
Subject: RE: Interview

Hi John – sorry we are still trying to get something arranged. Could you send your questions.

Thanks,

Jen

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
From: Fauci, Anthony (NIH/NIAID) [E]  
Sent: Sun, 26 Apr 2020 21:00:27 +0000  
To: Conrad, Patricia (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]  
Subject: RE: BOLIVIAN COVID-19 GUIDELINES

I cannot co-author anything with them. Make sure they do not slip my name in.

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (301) 496-4409  
E-mail: (b)(6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E]  
Sent: Saturday, April 25, 2020 7:20 AM  
To: Fauci, Anthony (NIH/NIAID) [E] (b)(6); Folkers, Greg (NIH/NIAID) [E] (b)(6)  
Subject: Fwd: BOLIVIAN COVID-19 GUIDELINES

Sent from my iPhone

Begin forwarded message:

From: Quispe Cornejo Armin Alvaro (b)(6)  
Date: April 25, 2020 at 5:30:30 AM EDT  
To: "Conrad, Patricia (NIH/NIAID) [E] (b)(6), "Barasch, Kimberly (NIH/NIAID) [C]" (b)(6)  
Cc: (b)(6)  
Subject: BOLIVIAN COVID-19 GUIDELINES

Dear Ms. Patricia Conrad
Dear Ms. Kimberly Marie Barasch

I hope you are well despite the current devastating world pandemic.

The **Bolivian Society of Intensive Care** together with the **Bolivian Healthcare Ministry** are writing the national guidelines for the management of COVID-19 in the critically ill patient, an issue that is an emergency worldwide and may become disastrous in the low-middle income countries of Latin America if not managed since the beginning with precise, accurate and uniform approaches.

With our team in Erasme University Hospital in Brussels, Belgium, together with Professors Jean - Louis Vincent, Fabio Taccone, Jean Charles Preiser, Jacques Creteur, etc., we are preparing the material with other Bolivian and Mexican intensivists, internists, infectologists, imagenologists.

I wonder if Dr. Anthony Fauci would honor us coauthoring and reviewing our last version of some chapters of our guidelines.

Best regards,

**AAQC**

---

**SPE - CORNEJO,**

medicine PhD fellow (Fell.)

**M/MX** — Internista

**Aparición [UNAM]** — Medicina Interna

**Diabetesología — Educación**

— SIZ member

**8177**
Thank you!

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (301) 496-4409  
E-mail  

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Dear Tony,

we are all witnessing the great effort your collaborators and yourself are investing over this pandemic emergency.

As you well know, in Europe and Italy we had the unfortunate privilege of having been first hit hard by the pandemic, after China.

We had the opportunity of meta-analyzing data from 170,000 patients in European countries, for associated determinants of the spreading force of COVID-19.

If this may provide a useful, albeit non gratifying, contribution for the US and other countries, we would feel we had done our job.

best wishes

Saverio
Prof. Saverio Alberti
Genetica Medica
Dipartimento di Scienze Biomediche
Università di Messina
Policlinico “G. Martino”
via Consolare Valeria
98125 Messina
Thank you for sending this.
Best regards,
AS Fauci

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-0673
FAX: (301) 496-4409
E-mail: anthony.fauci@nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Dear Dr. A. Fauci,

we don't know each other. I was bom (b) I am a simple doctor in Medicin and live in a remote Italian region. I am no one. I trust in God that you can read my paper, being published. I send it to you to anticipate the exit times because I trust that we can really understand what Covid 19 is. Being nobody, I did what nobody would have done. I used the few tools I had available and questioned all the papers and data published so far. I describe what the dual mechanism of the Covid-19 can be. I anticipate that the result conclusion is not to my credit but I have been helped. I wish you a good read. May God bless us.

Sincerely with love,
Dr. Carlo Brogna M.D.

Italia
Avellino-Isernia
Thank you, Delia. I appreciate the information.

Best regards,

Tony

---

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4409
FAX: (301) 496-4409
E-mail:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

From: Goletti Delia
Sent: Friday, April 17, 2020 8:03 AM
To: Fauci, Anthony (NIH/NIAID) [E]; Fabrizio Cantini
Cc: Lerner, Andrea (NIH/NIAID) [E]; Cassetti, Cristina (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]; Greg Folkers
Subject: impact of baricitinib in COVID-19-an off label study CONFIDENTIAL

dear Dr. Fauci, good morning. I hope you are fine.

Apologies to disturb you but it may be of your interest. I saw in the web that you (NIAID/Fauci) [https://investor.lilly.com/news-releases/news-release-details/lilly-begins-clinical-testing-therapies-covid-19] will be support a trial using Baricitinib as part of the ACTT trial...

I collaborated with Fabrizio Cantini (he reads in cc), a rheumatologist of Prato to write a letter to J Infection (pdf attached). He conducted an off-label study in patients with mild-moderate pneumonia with COVID-19 ([SpO2] >92% at room-air, and ratio arterial oxygen partial pressure/fractional inspired oxygen (PaO2/FiO2) 100-300 mmHg) to evaluate the impact of baricitinib (tablet 4 mg/day) in terms of safety, clinical respiratory improvements, discharge, ICU transfer in 2 weeks; these patients received also lopinavir/ritonavir therapy. The last consecutive patients with moderate COVID-19 pneumonia receiving standard of care therapy (lopinavir/ritonavir and hydroxychloroquine) admitted before the date of the first baricitinib-treated patient served as controls.
The results of this off-label study, with the limit of not been a RCT, are encouraging:

1. Safety: only 1/12 case of transaminase elevation at day 10, likely due to lopinavir ritonavir co-administration because baricitinib is mainly renal secreted
2. Respiratory improvement: SpO2 and ratio arterial oxygen partial pressure/fractional inspired oxygen (PaO2/FiO2) significantly improved;
3. Discharge in 7/12 vs 1/12
4. ICU transfer (0/12 vs 4/12)

I do hope it may be a useful, although I am aware that it is a very preliminary info for you.

Thank you for your attention.

All the best
Delia

---

Da: Fauci, Anthony (NIH/NIAID) [E]
Invio: giovedi 15 aprile 2020 00:02
A: Goletti Delia
Oggetto: RE: Italian press...for you!

Delia:

Thank you very much for sending these.
Best regards,
Tony

---

From: Goletti Delia
Sent: Wednesday, April 15, 2020 2:51 PM
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Italian press...for you!

Dear Dr Fauci, I disturb you only to let you know that the Italian press is with you!
Dr Ippolito asked me to contribute to prepare a document in support of you which I did with all my hearth. I gave my very minor contribution in supporting the scientific journalist, but with a lot of pride for you.

If you do not have it, below are some of the links in your favor.

https://apnews.com/27feca21519a5eaf555c01313d33b91
https://apnews.com/b59d0a2c4c53f1c63a074b0d375fec23
https://www.repubblica.it/salute/medicina-e-ricerca/2020/04/15/news/per_favore_non_silurare_anthony_fauci-254087254/
https://www.adnkronos.com/latti/cronaca/2020/04/15/coronavirus-pazienti-dimessi-dallospallanzani_puDuaZKkoJNyLCZlDgPN.html

all the best
Delia

Da: Goletti Delia
Invio: domenica 12 aprile 2020 19:57
A: Fauci, Anthony (NIH/NIAD) [E] (b)(6)
Oggetto: R: all my gratitude and an update

Thank you for your time!
Best regards

Da: Fauci, Anthony (NIH/NIAD) [E] (b)(6)
Invio: domenica 12 aprile 2020 19:53
A: Goletti Delia (b)(6)
Oggetto: RE: all my gratitude and an update

Delia:
Many thanks for your kind note. It is much appreciated. I am pleased to see that you are getting involved in COVID-19 work. Keep up your excellent work.
Best regards,
Tony

From: Goletti Delia (b)(6)
Sent: Sunday, April 12, 2020 11:02 AM
To: Fauci, Anthony (NIH/NIAD) [E] (b)(6)
Subject: all my gratitude and an update

dear Dr Fauci, apologies to write you in these busy days. It is only to express all my gratitude for what you have done in your life to fight infectious diseases and what you are doing now for COVID-19. Your efforts and achievement are in front of the whole world and for me it is a great honor to have been with you in 1992-1996 at the time of HIV fight. As I told you many times, you are a model of excellence!

Only to keep you updated in my life, I am fine, and I mainly work as an ID specialist and scientist at the same place in Rome, the National Institute for Infectious Diseases L. Spallanzani. I am doing 2 days a week outpatients TB clinic and I run a small laboratory on TB research. However, given the pandemic, I shifted the lab activities on COVID-19, in particular on:

1. the role of coinfection (COVID-19 coinfection with tuberculosis, or COVID-19 coinfection with HIV) on the modulation of the in vitro immune specific-response to SARS-CoV-2, or M. tuberculosis or HIV in cells from COVID-19 patients at different clinical stage
2. in vitro evaluation of the immunological and virological effect of baricitinib, an anti-JAK1 and -JAK2 drugs, used in rheumatoid arthritis, that has shown using BenevolentAI’s proprietary artificial intelligence-derived knowledge graph, as an agent that reduces the SARS-CoV-2 endocytosis into target cells potentially inhibiting the entry.

Moreover, I would be happy to contribute in any activity you may think I am useful.

I wish you a happy Easter in this blessed day.

Thank you for your attention and for having had the possibility of working with you that has been crucial in my personal and professional life.

All the best
Delia

Delia Goletti, MD, PhD
Clinical Investigator, Laboratorio del Vecchio, Room 13
Head of Translational Research Unit
Department of Epidemiology and Preclinical Research National Institute for Infectious Diseases L. Spallanzani
Via Portuense 292, Roma 00145 Italy
Tel: (6) 39-06-5582-325
Fax: +39-06-5582-325
E-mail address: dgoletti@imim.it
http://www.imi.it/ricerca_traslazionale.html; http://www.imi.it/ricerca_traslazionale English.html

Professor of Pathology,
Unicamillus University
Rome, Italy

Visiting Professor,
Centre for Immunobiology,
Bicardi Institute,
Queen Mary University of London, UK

Top Italian Women Scientist
From: Fauci, Anthony (NIH/NIAID) [E]  
Sent: Wed, 22 Apr 2020 14:41:51 -0000  
To: Billet, Courtney (NIH/NIAID) [E]  
Subject: RE: Expert U.S. panel develops NIH treatment guidelines for COVID-19

Please send me our press release related to the guidelines

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (301) 496-4409  
FAX: (301) 496-4409  
E-mail:  

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E]  
Sent: Tuesday, April 21, 2020 8:46 PM  
To: Fauci, Anthony (NIH/NIAID) [E]  
Cc: Lane, Cliff (NIH/NIAID) [E]; Masur, Henry (NIH/CC/CCMD) [E]  
Conrad, Patricia (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Pau, Alice (NIH/NIAID) [E]; Doepel, Laurie (NIH/NIAID) [E]  
Subject: FW: Expert U.S. panel develops NIH treatment guidelines for COVID-19

Your thoughts on Cliff et al doing a COCA call about the new guidelines?  
(COCA= CDC's Clinician Outreach and Communication Activity)

From: Billet, Courtney (NIH/NIAID) [E]  
Sent: Tuesday, April 21, 2020 8:37 PM  
To: Lane, Cliff (NIH/NIAID) [E]; Masur, Henry (NIH/CC/CCMD) [E]; Pau, Alice (NIH/NIAID) [E]; Doepel, Laurie (NIH/NIAID) [E]  
Subject: RE: Expert U.S. panel develops NIH treatment guidelines for COVID-19

We don't have to decide this tonight....
From: Lane, Cliff (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, April 21, 2020 8:20 PM
To: Billet, Courtney (NIH/NIAID) [E] (b) (6); Masur, Henry (NIH/CC/CCMD) [E] (b) (6)
Cc: Pau, Alice (NIH/NIAID) [E] (b) (6); Doepel, Laurie (NIH/NIAID) [E] (b) (6)
Subject: Re: Expert U.S. panel develops NIH treatment guidelines for COVID-19

From: "Billet, Courtney (NIH/NIAID) [E]" (b) (6)
Date: Tuesday, April 21, 2020 at 3:49 PM
To: "Lane, Cliff (NIH/NIAID) [E]" <(b) (6), "Masur, Henry (NIH/CC/CCMD) [E]" (b) (6)
Cc: "Pau, Alice (NIH/NIAID) [E]" (b) (6), Laurie Doepel (b) (6)
Subject: FW: Expert U.S. panel develops NIH treatment guidelines for COVID-19

Please advise?

From: Hall, Bill (HHS/ASPA) (b) (6)
Sent: Tuesday, April 21, 2020 3:46 PM
To: Billet, Courtney (NIH/NIAID) [E] <(b) (6)
Subject: FW: Expert U.S. panel develops NIH treatment guidelines for COVID-19

Would Cliff and company want to participate in a COCA call that CDC could put on?

From: Bonds, Michelle E. (CDC/OD/OADC) (b) (6)
Sent: Tuesday, April 21, 2020 2:44 PM
To: Hall, Bill (HHS/ASPA) (b) (6)
Subject: FW: Expert U.S. panel develops NIH treatment guidelines for COVID-19

I see the NIH treatment guidelines news release is out. Are you still interested in hosting a COCA call on these guidelines?

Subject: FW: Expert U.S. panel develops NIH treatment guidelines for COVID-19

Just out, press release from NIH:

**Expert U.S. panel develops NIH treatment guidelines for COVID-19**

04/21/2020 11:30 AM EDT

“Living document” expected to be updated often as new clinical data accrue.
Expert U.S. panel develops NIH treatment guidelines for COVID-19

“Living document” expected to be updated often as new clinical data accrue.
A panel of U.S. physicians, statisticians, and other experts has developed treatment guidelines for coronavirus disease 2019 (COVID-19). These guidelines, intended for healthcare providers, are based on published and preliminary data and the clinical expertise of the panelists, many of whom are frontline clinicians caring for patients during the rapidly evolving pandemic. The guidelines are posted online (covid19treatmentguidelines.nih.gov) and will be updated often as new data are published in peer-reviewed scientific literature and other authoritative information emerges.

The guidelines consider two broad categories of therapies currently in use by healthcare providers for COVID-19: antivirals, which may target the coronavirus directly, and host modifiers and immune-based therapies, which may influence the immune response to the virus or target the virus.

The panel’s conclusions about treating COVID-19 with various agents that fall into these two classes of therapies are distilled in summary recommendations. Subsequently, the document provides background information about each agent—such as clinical data about its use, ongoing clinical trials, and known interactions with other drugs—that forms the basis for the Recommendation. Tables briefly outline the same information.

The guidelines also describe the evaluation and stratification of patients based on their risk of infection and severity of illness. Recommendations in this section address best practices for managing patients at different stages of infection, for example:

- Outpatients who are either asymptomatic or who have mild to moderate symptoms and are self-isolating
- Inpatients with severe illness or critical disease

Special considerations for pregnant women and for children who are infected are also included.

A comprehensive section of the guidelines addresses a range of considerations for clinicians caring for the most critically ill hospitalized patients. This section includes multiple
recommendations for patients needing critical care, including infection control procedures, hemodynamic and ventilatory support, and drug therapy.

Finally, the guidelines include recommendations concerning the use of concomitant medications. These include statins; corticosteroids; non-steroidal anti-inflammatory drugs; and certain drugs used to control hypertension, known as ACE inhibitors and ARBs.

The treatment guidelines panel is co-chaired by Roy M. Gulick, M.D., chief of the Infectious Disease Division at Weill Medical Hospital of Cornell University, New York City; H. Clifford Lane, M.D., clinical director of the National Institute of Allergy and Infectious Diseases, National Institutes of Health; and Henry Masur, M.D., chief of the Critical Care Medicine Department at the NIH Clinical Center. Members of the guidelines panel, appointed by the co-chairs, were chosen based on their clinical experience and expertise in patient management, translational and clinical science, and/or the development of treatment guidelines. They include 30 experts drawn from U.S. healthcare and academic organizations, federal agencies, and professional societies.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
Expert U.S. panel develops NIH treatment guidelines for COVID-19

04/21/2020 11:30 AM EDT

“Living document” expected to be updated often as new clinical data accrue.

Update Your E-mail Address | Add Subscriptions | Unsubscribe

If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. For all other inquiries about NIH programs and activities, please contact Ask NIH. Before writing, please view our Frequently Asked Questions page, our Health Information page, or Search our website.

This service is provided to you by the National Institutes of Health.

NIH...Turning Discovery Into Health®

This email was sent to en7@cdc.gov using GovDelivery Communications Cloud on behalf of: National Institutes of Health (NIH) · 9000 Rockville Pike · Bethesda MD 20892 · 301-496-4000 / TTY 301-402-9612
Peter:

Happy to discuss at your convenience — sooner rather than later. Let us make sure that we

Happy to discuss this in detail with you.

Best regards,

Tony

From: Marks, Peter [REDACTED]  
Sent: Thursday, April 23, 2020 5:50 PM  
To: Collins, Francis (NIH/OD) [REDACTED]; Fauci, Anthony (NIH/NIAID) [REDACTED]  
Cc: Mascola, John (NIH/VRC) [REDACTED]; Disbrow, Gary (OS/ASPR/BARDA)  
Subject: Vaccine Development

Dear Francis and Tony,

I know that you have heard murmuring about Project Warp Speed. We had a call today with John Mascola, Carl Dieffenbach, Hilary Marston, Mary Marovich and Emily Erbelding to go through the proposal and discuss how it could feed into the ACTIV effort. They suggested that I contact you to try to set up a brief call to go over the plan. I am attaching a slide deck that provides an overview and am happy to find the time whenever you are available.

Thanks so much for considering,

Peter
Here is the paper from Pittsburg on the mutations. I will send on separate e-mail the commentary from China on another study.

This is really getting interesting. See attachment.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Sorry for all of the emails. I spoke to Adam who is an oncologist. I thought this might be of interest.
Steve
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.
Subject: Serology Test Calculator

Attached is a very rudimentary calculator that you are welcome to share with the WHTF/HHS serology WG to calculate the positive predictive value and negative predictive value of individual serology tests and the use of two tests by plugging in the known or estimated sensitivity, specificity, and population prevalence of COVID-19.
I will call you about this.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.
### Calculator for Positive Predictive Value (PPV) and Negative Predictive Value (NPV) for individual tests and combined

<table>
<thead>
<tr>
<th>Test 1</th>
<th>Prevalence 5.0%</th>
</tr>
</thead>
<tbody>
<tr>
<td>%Pos1 (Test1=pos)</td>
<td>PPV1 for (Test1=pos)</td>
</tr>
<tr>
<td>97.0%</td>
<td>11.3%</td>
</tr>
<tr>
<td>Test 2</td>
<td></td>
</tr>
<tr>
<td>%Pos2 (Test2=pos)</td>
<td>PPV2 for (Test2=pos)</td>
</tr>
<tr>
<td>88.0%</td>
<td>8.2%</td>
</tr>
<tr>
<td>Combined</td>
<td></td>
</tr>
<tr>
<td>%Pos (Test1=pos, Test2=pos)</td>
<td>PPV for (Test1=pos, Test2=pos)</td>
</tr>
<tr>
<td>4.5%</td>
<td>94.3%</td>
</tr>
</tbody>
</table>
Great idea!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4409
E-mail: 

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Team,
Anand Shah, Deputy Commissioner, reached out to the Stanford investigators on our behalf. Very interesting information regarding their research and the test that they are using. They are interested in partnering with us. I'll let Anand give the details.

Anand will be reaching out to the MGH folks, as well.

Steve
Steve:

John Ioannidis is the one that most of us know. He is the person one of your people could reach out to.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4409
FAX: (301) 496-4409
E-mail: 

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

We can certainly work with them. Does anyone know any of these folks?
Steve:

Thanks for the quick reply. The data from the Stanford group

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hahn, Stephen (b) (6)
Sent: Saturday, April 18, 2020 10:31 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Birx, Deborah L. EOP/NSC (b) (6); Redfield, Robert R. (CDC/OD) (b) (6); Kadlec, Robert (OS/ASPR/IO) (b) (6); Caliguiri, Laura (FDA/OC) (b) (6); Lenihan, Keagan (FDA/OC) (b) (6); Shuren, Jeff (FDA/CDRH) (b) (6)
Subject: Re: medRxiv: COVID-19 Antibody Seroprevalence in Santa Clara County, California

Tony,
From: Fauci, Anthony (NIH/NIAID) [E]  
Date: April 18, 2020 at 10:03:32 AM EDT  
To: Hahn, Stephen  
Cc: Birx, Deborah L. EOP/NSC, Redfield, Robert R (CDC)  
Kadlec, Robert P (OS)  
Subject: FW: medRxiv: COVID-19 Antibody Seroprevalence in Santa Clara County, California

Steve:  

Thanks,  
Tony

From: Folkers, Greg (NIH/NIAID) [E]  
Sent: Friday, April 17, 2020 5:44 PM  
Subject: medRxiv: COVID-19 Antibody Seroprevalence in Santa Clara County, California

COVID-19 Antibody Seroprevalence in Santa Clara County, California
Eran Bendavid, Bianca Mulaney, Neeraj Sood, Soleil Shah, Emilia Ling, Rebecca Bromley-Dulfano, Cara Lai, Zoe Weissberg, Rodrigo Saavedra, James Tedrow, Dona Tversky, Andrew Bogan, Thomas Kupiec, Daniel Eichner, Ribhav Gupta, John Ioannidis, Jay Bhattacharya


- Abstract
- Info/History
- Metrics
- Preview PDF
Abstract
Background Addressing COVID-19 is a pressing health and social concern. To date, many epidemic projections and policies addressing COVID-19 have been designed without seroprevalence data to inform epidemic parameters. We measured the seroprevalence of antibodies to SARS-CoV-2 in Santa Clara County. Methods On 4/3-4/4, 2020, we tested county residents for antibodies to SARS-CoV-2 using a lateral flow immunoassay. Participants were recruited using Facebook ads targeting a representative sample of the county by demographic and geographic characteristics. We report the prevalence of antibodies to SARS-CoV-2 in a sample of 3,330 people, adjusting for zip code, sex, and race/ethnicity. We also adjust for test performance characteristics using 3 different estimates: (i) the test manufacturer's data, (ii) a sample of 37 positive and 30 negative controls tested at Stanford, and (iii) a combination of both. Results The unadjusted prevalence of antibodies to SARS-CoV-2 in Santa Clara County was 1.5% (exact binomial 95CI 1.11-1.97%), and the population-weighted prevalence was 2.81% (95CI 2.24-3.37%). Under the three scenarios for test performance characteristics, the population prevalence of COVID-19 in Santa Clara ranged from 2.49% (95CI 1.80-3.17%) to 4.16% (2.58-5.70%). These prevalence estimates represent a range between 48,000 and 81,000 people infected in Santa Clara County by early April, 50-85-fold more than the number of confirmed cases. Conclusions The population prevalence of SARS-CoV-2 antibodies in Santa Clara County implies that the infection is much more widespread than indicated by the number of confirmed cases. Population prevalence estimates can now be used to calibrate epidemic and mortality projections.
Go for it. Congratulations!!! 😊

Hi Tony,

I’ve told John B/Renate/Courtney that everything can post first thing tomorrow morning.

Best regards,
Bill

Katie/Marc:

Just as an FYI – “The Coronavirus Disease 2019 (COVID-19) Treatment Guidelines” that were developed here at NIH, and a copy of which I provided to Deb Birx and ultimately to Mark Meadows is moving forward. Mark Meadows
Press release will come from NIH with clearance through the appropriate channels (see attachment as an FYI). I anticipate that this will happen in the next day or two.

Thanks.

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.
Correct again.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4409
E-mail: 

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender’s own and not expressly made on behalf of the NIAID by one of its representatives.

Subject: RE: ask to highlight the incredible work of key federal workers
From: Folkers, Greg (NIH/NIAID) [E] <gtfolkers@niaid.nih.gov>
Sent: Monday, April 20, 2020 4:52 PM
To: Billet, Courtney (NIH/NIAID) [E] <billete@niaid.nih.gov>; NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Cc: Stover, Kathy (NIH/NIAID) [E] <kathy.stover@nih.gov>; Routh, Jennifer (NIH/NIAID) [E]
<jennifer.ro ethn@nih.gov>
Subject: RE: ask to highlight the incredible work of key federal workers

Let us discuss. Any suggestions?

From: Billet, Courtney (NIH/NIAID) [E] <billete@niaid.nih.gov>
Sent: Monday, April 20, 2020 4:40 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Cc: Stover, Kathy (NIH/NIAID) [E] <kathy.stover@nih.gov>; Routh, Jennifer (NIH/NIAID) [E]
Subject: FW: ask to highlight the incredible work of key federal workers

From: Boyse, Natalie (OS/ASPA) <(b)(6)>
Sent: Monday, April 20, 2020 4:28 PM
To: Billet, Courtney (NIH/NIAID) [E] <billette@niaid.nih.gov> ; Myles, Renate (NIH/OD) [E]
 burklow, John (NIH/OD) [E] <(b)(6)>
Cc: Bird, Catherine (OS/OGC) <(b)(6) >; Brennan, Patrick (OS/ASPA) <(b)(6)>
Subject: FW: ask to highlight the incredible work of key federal workers

Hi John, Renate and Courtney —
Let me know if you have any questions re: this request. I am available and happy to chat this afternoon.

Thanks,
Natalie

Natalie Boyse
Special Assistant, Immediate Office of the Secretary
U.S. Department of Health & Human Services

From: Baldwin, Brittany L. EOP/WHO <(b)(6)>
Sent: Monday, April 20, 2020 3:00 PM
To: Boyse, Natalie (OS/ASPA) <(b)(6)>
Subject: ask to highlight the incredible work of key federal workers

Hi Natalie – great talking just now.
Please do not hesitate to reach out with questions!

Brittany L. Baldwin
Special Assistant to the President
Speechwriter

O: (6) (6)
C: (5) (6)
I agree. Let us do it another time.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4409
E-mail: 

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender’s own and not expressly made on behalf of the NIAID by one of its representatives.

With apologies, I just realized that the ACTIV Vaccines working group (which involves John in a significant way, and will be joined today by Tal Zaks from Moderna) meets this morning from 9 – 10 am. Probably we need to pick another time for this pow-wow about the CVP?

Francis
Patty:

Please see if we can incorporate this call into our regularly scheduled 9:00 AM call that actually includes some of the same cast of people.

Thanks,
Tony

Got it,

Can we have a phone call about this tomorrow at 9:15 am? Anyone else to include (Emily? Cliff?)

Francis


Cc: Conrad, Patricia (NIH/NIAID) [E]  (b) (6)
Subject: RE: Pursuant to My Email on Friday

Francis:

(b) (5)
Best,
Tony

From: Mascola, John (NIH/VRC) [E]  (b) (6)
Sent: Sunday, April 19, 2020 4:24 PM
To: Fauci, Anthony (NIH/NIAID) [E]  (b) (6) >; Collins, Francis (NIH/OD) [E]  (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E]  (b) (6) >
Subject: FW: Pursuant to My Email on Friday

<< File: Cov Vaccine Program HHS (draft) 19April20.pptx >>

Tony, Francis,
Happy to discuss.

John

From: Kadlec, Robert (OS/ASPR/IO)  
Sent: Sunday, April 12, 2020 8:59 PM
To: Hassell, David (Chris) (OS/ASPR/IO)  
Collins, Francis (NIH/OD) [E]  
Bright, Rick (OS/ASPR/BARDA) [E]  
Fauci, Anthony (NIH/NIAID) [E]  
Disbrow, Gary (OS/ASPR/BARDA)  
Patrick, Vanessa (OS/ASPR/BARDA) (CTR)  
Moughalian, Jen (HHS/ASFR)  
Redfield, Robert R. (CDC/OD)  
Messonnier, Nancy (CDC/DDID/NCIRD/OD)  
Lane, Cliff (NIH/NIAID) [E]  
Marks, Peter (FDA/CBER)  
Yeskey, Kevin (OS/ASPR/IO)  
Harrison, Brian (HHS/IOS)  
Dareshori, Zack (HHS/IOS)  
Conrad, Patricia (NIH/NIAID) [E]  
Stecker, Judy (OS/IOS)  
Shuy, Bryan (OS/ASPR/IO)  
Wolinetz, Carrie (NIH/OD) [E]  
Subject: Pursuant to My Email on Friday

I want to share with you the product of the BCG team who drafted the attached briefing and Decision Memo drafted for the Secretary’s review tomorrow. I want to thank all those who contributed over this holiday weekend to offer their ideas and concepts that is represented in these products. This represents just a first step of many steps that first outlines a concept that will then be operationalized into a historic effort for not only the Department and agencies who will contribute to it, but our Nation. Again, thank you for your contributions and commitment. Best Bob
OK. Let us discuss tomorrow.

Tony,

One key point that may be easier to review with 5 min call, whenever you get the chance.

John

Francis,
If still not so clear, feel free to call.

John

From: Collins, Francis (NIH/OD) [E]
Sent: Sunday, April 19, 2020 5:04 PM
To: Mascola, John (NIH/VRC) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]
Subject: RE: Pursuant to My Email on Friday

Hi John,

Thanks for your thoughtful note.

Francis
From: Mascola, John (NIH/VRC) [E]
Sent: Sunday, April 19, 2020 4:24 PM
To: Fauci, Anthony (NIH/NIAID) [E]; Collins, Francis (NIH/OD) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Pursuant to My Email on Friday

<< File: Cov Vaccine Program HHS (draft) 19April20.pptx >>

Tony, Francis,
From: Kadlec, Robert (OS/ASPR/IO) (b)(6)  
Sent: Sunday, April 12, 2020 8:59 PM  
To: Hassell, David (Chris) (OS/ASPR/IO) (b)(6)  
Collins, Francis (NIH/OD) [E] (b)(6)  
Mascola, John (NIH/VRC) [E] (b)(6)  
Bright, Rick (OS/ASPR/BARDA) (b)(6)  
Fauci, Anthony (NIH/NIAID) [E] (b)(6)  
Disbrow, Gary (OS/ASPR/BARDA) (b)(6)  
Patrick, Vanessa (OS/ASPR/BARDA) (CTR) (b)(6)  
Moughalian, Jen (HHS/ASFR) (b)(6)  
Redfield, Robert R. (CDC/OD) (b)(6)  
Messonnier, Nancy (CDC/DDID/NCIRD/OD) (b)(6)  
Lane, Cliff (NIH/NIAID) [E] (b)(6)  
Marks, Peter (FDA/CBER) (b)(6)  
Yeskey, Kevin (OS/ASPR/IO) (b)(6)  
Cc: Harrison, Brian (HHS/IOS) (b)(6)  
Dareshori, Zack (HHS/IOS) (b)(6)  
Conrad, Patricia (NIH/NIAID) [E] (b)(6)  
Stecker, Judy (OS/IOS) (b)(6)  
Shuy, Bryan (OS/ASPR/IO) (b)(6)  
Wolinetz, Carrie (NIH/OD) [E] (b)(6)  
Subject: Pursuant to My Email on Friday

I want to share with you the product of the BCG team who drafted the attached briefing and Decision Memo drafted for the Secretary’s review tomorrow. I want to thank all those who contributed over this holiday weekend to offer their ideas and concepts that is represented in these products. This represents just a first step of many steps that first outlines a concept that will then be operationalized into a historic effort for not only the Department and agencies who will contribute to it, but to our Nation. Again, thank you for your contributions and commitment. Best Bob

<< File: Vaccine strategy-200411-v 13.pptx >>  
<< File: Secretary Determination Memorandum-Project Warp Speed-041120 1825 draft.doc >>
Please make sure that I call this person tomorrow.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4423
FAX: (301) 496-4409
E-mail: fauci@nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Dr. Fauci,

Thank you for responding to my request for information. Please be safe.

My cell phone number is (b)(6).

r/

From: Fauci, Anthony (NIH/NIAID) [E]  (b)(6)
Sent: Tuesday, April 21, 2020 12:49 PM
To: Fauci, Anthony (NIH/NIAID) [E]  (b)(6)
Cc: Lerner, Andrea (NIH/NIAID) [E]  (b)(6)
Subject: [Non-DoD Source] FW: Coronavirus Questions for the Office of the Surgeon General
Thank you for your note. Shown below are my answers to your questions. I hope that you find them helpful.

1. How do you recommend I reassure our staff on dealing with the stressors of COVID-19? 
This is indeed an unprecedented and stressful time. Stress can often come from the unknown. In times of stress it is critical to take care of one’s physical health, by eating well, getting enough sleep, and exercising. In addition, maintaining connections with family and friends (via phone calls, email, or video chatting) while physically socially distancing is very important.

2. Can COVID-19 be contracted from a corpse? 

3. If someone has been a user of Hydroxychloroquine for years, are they susceptible to contracting COVID-19? 
Clinical trials are underway to determine if hydroxychloroquine is effective in preventing COVID-19 in exposed persons. Until we know the answer to this question, persons who take hydroxychloroquine on a daily basis for another medical condition should consider themselves vulnerable to COVID-19 and take appropriate and recommended measures to protect themselves.

4. Are masks and gloves truly effective, if so, why are so many medical professionals contracting the virus? 
In cases where inadequate PPE is worn, or if is not put on/taken off according to proper procedure, the risk of contracting COVID is increased. In addition, healthcare workers on the front lines can be exposed if they encounter a patient who is not initially suspected of having COVID-19 without PPE, especially if they are exposed to aerosol generating processes.
5. What is the most important thing we should be doing, other than social distancing?
Social distancing is key in order to avoid coming into contact with someone with COVID-19, but washing one's hands often (or using an alcohol-based hand sanitizer) and avoiding touching one's face with unwashed hands are critical as well, especially when coming into contact with surfaces that may have been touched by others or public places.

6. Finally, what keeps you up at night, regarding COVID-19?
I have said in the past that what keeps me up at night is the possibility of a pandemic respiratory infection. We are in that reality now, and what keeps me up at night is the response, a major part of which is the development of an effective vaccine and treatments for COVID-19.

Best regards,
Tony
Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6) 496-4409
FAX: (301) 496-4409

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6) MEDCOM (USA) (b) (6)
Sent: Tuesday, April 14, 2020 9:13 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Coronavirus Questions for the Office of the Surgeon General

Dr. Fauci,

I am (b) (6), the antiterrorism and insider threat officer for the Office of the Surgeon General (Army) / U.S. Army Medical Command. I have been in government for nearly thirty-four years, and this is new to me. I see and hear the concerns of many people. You are the voice of reason for millions of concerned citizens. I have a few questions for you:

1. How do you recommend I reassure our staff on dealing with the stressors of COVID-19?
2. Can COVID-19 be contracted from a corpse?
3. If someone has been a user of Hydroxychloroquine for years, are they susceptible to contracting COVID-19?
4. Are masks and gloves truly effective, if so, why are so many medical professionals contracting the virus?
5. What is the most important thing we should be doing, other than social distancing?

Finally, what keeps you up at night, regarding COVID-19?

Thank you for your time and please be safe.

/r/ Antiterrorism and Insider Threat Officer
Office of the Surgeon General and U.S. Army Medical Command
Mission Assurance and Protection Division
Fort Sam Houston, TX 78234
Cell phone: 
NIPRNet: 
SIPRNet: 
Level I Antiterrorism Awareness Training:

Organizational Mailbox:
mailto: 
To submit contracts for AT/OPSEC review:
Caution-
"Not on My Watch"

CONFIDENTIALITY NOTE: This electronic transmission, including all attachments, is directed in confidence solely to the person(s) to whom it is addressed, or an authorized recipient, and may not otherwise be distributed, copied or disclosed. The contents of the transmission may also be subject to intellectual property rights and all such rights are expressly claimed and are not waived. If you received this transmission in error, please notify the sender immediately by returning the electronic transmission and then immediately delete this transmission, including all attachments, without copying, distributing or disclosing same.

"PRIVACY ACT INFORMATION"

In compliance with the Privacy Act of 1974, this information is Personal Data and must be protected from public disclosure.
Thank you for your note. Shown below are my answers to your questions. I hope that you find them helpful.

1. How do you recommend I reassure our staff on dealing with the stressors of COVID-19?
   This is indeed an unprecedented and stressful time. Stress can often come from the unknown. In times of stress it is critical to take care of one’s physical health, by eating well, getting enough sleep, and exercising. In addition, maintaining connections with family and friends (via phone calls, email, or video chatting) while physically socially distancing is very important.

2. Can COVID-19 be contracted from a corpse?
   Infection control measures should be undertaken when dealing with deceased individuals with known or suspected COVID-19. The CDC provides guidance on this issue here: https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-postmortem-specimens.html

3. If someone has been a user of Hydroxychloroquine for years, are they susceptible to contracting COVID-19?
   Clinical trials are underway to determine if hydroxychloroquine is effective in preventing COVID-19 in exposed persons. Until we know the answer to this question, persons who take hydroxychloroquine on a daily basis for another medical condition should consider themselves vulnerable to COVID-19 and take appropriate and recommended measures to protect themselves.

4. Are masks and gloves truly effective, if so, why are so many medical professionals contracting the virus?
   In cases where inadequate PPE is worn, or if is not put on/taken off according to proper procedure, the risk of contracting COVID is increased. In addition, healthcare workers on the front lines can be exposed if they encounter a patient who is not initially suspected of having COVID-19 without PPE, especially if they are exposed to aerosol generating processes.

5. What is the most important thing we should be doing, other than social distancing?
   Social distancing is key in order to avoid coming into contact with someone with COVID-19, but washing one’s hands often (or using an alcohol-based hand sanitizer) and avoiding touching one’s face with unwashed hands are critical as well, especially when coming into contact with surfaces that may have been touched by others or public places.
6. Finally, what keeps you up at night, regarding COVID-19?
   I have said in the past that what keeps me up at night is the possibility of a pandemic respiratory
   infection. We are in that reality now, and what keeps me up at night is the response, a major
   part of which is the development of an effective vaccine and treatments for COVID-19.

Best regards,

Tony
Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [b](6)
FAX: (301) 496-4409
E-mail: [b](6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive
information. It should not be used by anyone who is not the original intended recipient. If you
have received this e-mail in error please inform the sender and delete it from your mailbox or any
other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not
accept liability for any statements made that are the sender's own and not expressly made on
behalf of the NIAID by one of its representatives.

From: [b](6) MEDCOM (USA) [b](6)
Sent: Tuesday, April 14, 2020 9:13 AM
To: Fauci, Anthony (NIH/NIAID) [E] [b](6)
Subject: Coronavirus Questions for the Office of the Surgeon General

Dr. Fauci,

I am [b](6) the antiterrorism and insider threat officer for the Office of the Surgeon General
(Army) / U.S. Army Medical Command. I have been in government for nearly thirty-four years, and this
is new to me. I see and hear the concerns of many people. You are the voice of reason for millions of
concerned citizens. I have a few questions for you:

1. How do you recommend I reassure our staff on dealing with the stressors of COVID-19?
2. Can COVID-19 be contracted from a corpse?
3. If someone has been a user of Hydroxychloroquine for years, are they susceptible to contracting
   COVID-19?
4. Are masks and gloves truly effective, if so, why are so many medical professionals contracting
   the virus?
5. What is the most important thing we should be doing, other than social distancing?

Finally, what keeps you up at night, regarding COVID-19?
Thank you for your time and please be safe.

r/
(b)(6), Antiterrorism and Insider Threat Officer
Office of the Surgeon General and U.S. Army Medical Command
Mission Assurance and Protection Division
Fort Sam Houston, TX 78234
Cell phone: (b)(6)

NIPRNet: (b)(6)
SIPRNet: (b)(6)
Level I Antiterrorism Awareness Training:
http://iko.jten.mil/courses/atl1/launch.html

Organizational Mailbox: (b)(6)

To submit contracts for AT/OPSEC review: (b)(6)

"Not on My Watch"

CONFIDENTIALITY NOTE: This electronic transmission, including all attachments, is directed in confidence solely to the person(s) to whom it is addressed, or an authorized recipient, and may not otherwise be distributed, copied or disclosed. The contents of the transmission may also be subject to intellectual property rights and all such rights are expressly claimed and are not waived. If you received this transmission in error, please notify the sender immediately by returning the electronic transmission and then immediately delete this transmission, including all attachments, without copying, distributing or disclosing same.

"PRIVACY ACT INFORMATION"

In compliance with the Privacy Act of 1974, this information is Personal Data and must be protected from public disclosure.
Please fashion some responses to his questions for me to send back to him
Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4009
FAX: (301) 496-4409
E-mail: 

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender’s own and not expressly made on behalf of the NIAID by one of its representatives.

Dr. Fauci,
I am the antiterrorism and insider threat officer for the Office of the Surgeon General (Army) / U.S. Army Medical Command. I have been in government for nearly thirty-four years, and this is new to me. I see and hear the concerns of many people. You are the voice of reason for millions of concerned citizens. I have a few questions for you:

1. How do you recommend I reassure our staff on dealing with the stressors of COVID-19?
2. Can COVID-19 be contracted from a corpse?
3. If someone has been a user of Hydroxychloroquine for years, are they susceptible to contracting COVID-19?
4. Are masks and gloves truly effective, if so, why are so many medical professionals contracting the virus?
5. What is the most important thing we should be doing, other than social distancing?

Finally, what keeps you up at night, regarding COVID-19?
Thank you for your time and please be safe.

r/
(b)(6), Antiterrorism and Insider Threat Officer
Office of the Surgeon General and U.S. Army Medical Command
Mission Assurance and Protection Division
Fort Sam Houston, TX 78234
Cell phone: (b)(6)
NIPRNet: (b)(6)
SIPRNet: (b)(6)
Level I Antiterrorism Awareness Training:
http://iko.iten.mil/courses/atl1/launch.html
Organizational Mailbox: (b)(6)
To submit contracts for AT/OPSEC review: (b)(6)

"Not on My Watch"

CONFIDENTIALITY NOTE: This electronic transmission, including all attachments, is directed in confidence solely to the person(s) to whom it is addressed, or an authorized recipient, and may not otherwise be distributed, copied or disclosed. The contents of the transmission may also be subject to intellectual property rights and all such rights are expressly claimed and are not waived. If you received this transmission in error, please notify the sender immediately by returning the electronic transmission and then immediately delete this transmission, including all attachments, without copying, distributing or disclosing same.

"PRIVACY ACT INFORMATION"

In compliance with the Privacy Act of 1974, this information is Personal Data and must be protected from public disclosure.